AB 2365: Public health: kratom.
- Session Year: 2023-2024
- House: Assembly
- Latest Version Date: 2024-06-17
Current Status:
Failed
(2024-08-15: In committee: Held under submission.)
Introduced
In Committee
First Chamber
In Committee
Second Chamber
Enacted
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. A violation of the act is a crime.
This bill would add kratom products, as defined, to the Sherman Food, Drug, and Cosmetic Law and require processors of kratom products to register with the department. The bill would authorize the department to establish an annual fee for processors and would authorize the fee to be based on certain criteria, including annual sales in California. The bill would prescribe specified quantities of alkaloids present in kratom products and would establish labeling and packaging requirements. The bill would require that kratom products be registered with the department annually, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would prohibit the sale of kratom leaf and kratom products to those under 21 years of age. age and would prohibit the sale and manufacture of a kratom product that is attractive to children or an inhalable kratom product. The bill would authorize the department to take various enforcement actions, including executing interagency agreements for the implementation of these provisions, among others. The bill would authorize a kratom processor who is operating in conformance with these provisions and in good faith compliance with their responsibilities to manufacture or sell kratom or kratom products without authorization until April 1, 2025. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. A violation of the act is a crime.
This bill would add kratom products, as defined, to the Sherman Food, Drug, and Cosmetic Law and require processors of kratom products to register with the department. The bill would authorize the department to establish an annual fee for processors and would authorize the fee to be based on certain criteria, including annual sales in California. The bill would prescribe specified quantities of alkaloids present in kratom products and would establish labeling and packaging requirements. The bill would require that kratom products be registered with the department annually, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would prohibit the sale of kratom leaf and kratom products to those under 21 years of age. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. A violation of the act is a crime.
This bill would add kratom products, as defined, to the Sherman Food, Drug, and Cosmetic Law and require processors of kratom products to register with the department. The bill would prescribe specified quantities of alkaloids present in kratom products and would establish labeling and packaging requirements. The bill would require that kratom products be registered with the department annually, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would prohibit the sale of kratom leaf and kratom products to those under 18 21 years of age. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health (department) and in accordance with the Federal Food, Drug, and Cosmetic Act. A violation of the act is a crime.
This bill would state that it is the intention of the Legislature to enact legislation to regulate kratom. add kratom products, as defined, to the Sherman Food, Drug, and Cosmetic Law and require processors of kratom products to register with the department. The bill would prescribe specified quantities of alkaloids present in kratom products and would establish labeling and packaging requirements. The bill would require that kratom products be registered with the department annually, which would include certification by a laboratory specifying that the product meets certain qualifications. The bill would prohibit the sale of kratom leaf and kratom products to those under 18 years of age. By expanding the scope of a crime, the bill would create a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Sherman Food, Drug, and Cosmetic Law, provides for the regulation of various subjects relating to the manufacturing, processing, labeling, advertising, and sale of food, drugs, and cosmetics, under the administration and enforcement of the State Department of Public Health and in accordance with the Federal Food, Drug, and Cosmetic Act. A violation of the act is a crime.
This bill would state that it is the intention of the Legislature to enact legislation to regulate kratom.
As used in this article, the following terms have the following definitions:
(a)Attractive to children means any of the following:
(1)Use of images that are attractive to children, including, but not limited to, images of any of the following, except as part of required health warnings:
(A)Cartoons, toys, or robots.
(B)Any real or fictional humans.
(C)Any fictional animals or creatures.
(D)Fruits or vegetables, except when used to accurately describe ingredients or flavors contained in a product.
(2)Any likeness to images, characters, or phrases that are popularly used to advertise to children.
(3)Any imitation of candy packaging or labeling, or other packaging and labeling of cereals, sweets, chips, or other food products typically marketed to children.
(4)The terms candy or candies or variants in spelling such as kandy or kandee.
(5)Brand names or close imitations of brand names of candies, cereals, sweets, chips, or other food products typically marketed to children.
(6)Any other image or packaging that is easily confused with commercially available foods that do not contain kratom and are typically marketed to children.
(7)Anything else that the department determines in regulation to be attractive to children.
(8)Anything else that is attractive to children in light of all relevant facts and circumstances.
(a)(b)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. The total alkaloid content of kratom leaf material used in a kratom product shall not exceed 4 percent on a dried weight basis.
(b)(c)Kratom leaf extract means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
(1)That contains an amount of residual solvent not to exceed the amount specified in Chapter 467 of the United States Pharmacopeia and the National Formulary.
(2)That contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is more than twofold that of any other alkaloid present.
(3)The ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
(c)(d)(1)Kratom product means a food, ingredient, or dietary supplement that meets all of the following requirements:
(A)Consists of or contains kratom leaf or kratom leaf extract.
(B)Does not contain any synthesized kratom alkaloids or other synthesized kratom constituents, or synthesized metabolites of any kratom constituent.
(C)The level of 7-hydroxymitragynine on a percent weight basis is not greater than 1 percent of the amount of total kratom alkaloids confirmed with a high-performance liquid chromatography or an ultra-performance ultraperformance liquid chromatography testing method.
(2)For purposes of this subdivision, synthesized means produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
(d)(e)Processor means the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products.
(e)(f)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.81.(a)A kratom product produced, manufactured, distributed, sold, or offered for sale, if consisting of or containing kratom leaf extract, shall not exceed the amount specified for pharmaceutical products in Chapter 467 of the United States Pharmacopeia and the National Formulary of any residual solvent used in manufacturing of the extract.
(b)A product containing a synthesized kratom alkaloid or other synthesized kratom constituents, or synthesized metabolites of a synthesized kratom constituent, shall not be produced, manufactured, distributed, sold, or offered for sale.
111224.82.A kratom product produced, manufactured, distributed, sold, or offered for sale shall have a label that clearly and conspicuously provides all of the following information on each retail package:
(a)A recommendation against the use by individuals who are under 21 years of age, who are pregnant, or who are breastfeeding.
(b)A recommendation to consult a health care professional prior to use.
(c)An advisement that kratom may be habit forming.
(d)The following statement: These statements have not been evaluated by the United States Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
(e)The name and place of business of the processor, manufacturer, packer, or distributor.
(f)Directions for use that include all of the following:
(1)A recommended amount of the kratom product per serving.
(2)A recommended number of servings that can be safely consumed in a 24-hour period.
(3)Quantitative declarations of the amount per serving of each of the following:
(A)Total kratom alkaloids.
(B)Mitragynine.
(C)7-hydroxymitragynine.
111224.83.(a)A kratom product shall be packaged in a retail container that clearly marks the number of servings in the container.
(b)A kratom product offered for retail sale that is in liquid form and contains more than three servings shall include a calibrated measuring device.
(c)If the kratom product is in powdered form, the package shall include a calibrated measuring device.
111224.84.(a)A processor shall register pursuant to Section 111224.86 and shall annually register each kratom product it manufactures, packs, distributes, or labels. A product that contains the same kratom ingredients in the same kratom delivery form but a different container, package, or volume shall be included under the processors individual registration.
(b)Annual registration of a kratom product shall include a certificate of analysis from an independent laboratory. The laboratory shall be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
(c)The certificate of analysis shall confirm the contents of the kratom product, and include a certification that the product complies with the requirements for a kratom product described in Sections 111224.8 and 111224.81.
(d)The manufacturer shall certify that the kratom product does not contain a substance listed in Section 11054, 11055, 11056, 11057, or 11058.
(e)Upon receipt of evidence that suggests a kratom product may be adulterated, the department may require an independent third-party test of a registered kratom product by a laboratory of the departments choice, and the processor shall be required to submit payment for the test and equitable administrative fee within a reasonable timeframe. If the processor does not tender payment to the department within 30 days of receipt of the invoice for the testing and administrative fee, the department shall revoke the registration for that product.
111224.85.(a)An individual, business, or other entity shall not sell, offer for sale, provide, or distribute kratom leaf or a kratom product to a person under 21 years of age.
(b)An online retailer or marketplace of kratom leaf or a kratom product shall implement an age-verification system to ensure compliance with subdivision (a).
(c)An individual, business, or other entity shall not produce, sell, or distribute a kratom product that is attractive to children.
(d)The manufacture or sale of an inhalable kratom product is prohibited.
111224.86.(a)The department, in implementing this article, may establish an annual fee or assessment for any processor registering to produce, manufacture, or offer for sale kratom leaf or a kratom product. Except as otherwise required by law, an individual or entity registering pursuant to this article is not required to register pursuant to Article 2 (commencing with Section 110460).
(b)Commencing February 1, 2026, and every February 1 thereafter, the department shall report to the Legislature and publish both of the following on its internet website:
(1)A list of estimated fees.
(2)A report of all costs for activities of the Kratom Consumer Protection Program, including, but not limited to, both of the following:
(A)Projected workload and costs for applicants and annual registrants, including workload costs for inspection and enforcement activities.
(B)A staffing and systems analysis to ensure efficient and effective utilization of fees collected, proper allocation of departmental resources to registration activities, inspections, complaint investigations, enforcement and appeal activities, and data collection and reporting.
(c)A report to be submitted pursuant to subdivision (b) shall be submitted in compliance with Section 9795 of the Government Code.
(d)The department may develop registration fees based on the number of units produced by registrants and total annual sales in California. The fee schedule may consist of tiers of registration fees denoted by unit production, total annual sales in California, and corresponding fees to the number of units produced and annual sales in California. The fees shall not exceed the reasonable regulatory costs of administering this article. The calculation of estimated fees is exempt from the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
111224.87.A local authority shall not impose additional restrictions greater than those enumerated in this article or enact additional requirements on the manufacture of kratom leaf, kratom extract, or a kratom product.
111224.88.A kratom processor who is operating in conformance with this article and in good faith compliance with their responsibilities under this article may manufacture or sell kratom or kratom products without authorization until April 1, 2025.
111224.89.(a)A violation of this article shall be grounds for denying, suspending, forfeiting, revoking, or surrendering a registration.
(b)The department may deny, suspend, forfeit, revoke, or order to surrender a registration issued under this article when a peace officer, state official, or local official has notified the department that a processor within its jurisdiction is in violation of state law relating to this article, and the department, through an investigation, has determined that the violation is grounds for, or contributes to, other factors for denial, suspension, forfeiture, revocation, or surrender of the processors registration. An investigation conducted pursuant to this subdivision shall include reasonable notice to the processor and an opportunity for the processor to defend any allegations of a violation.
111224.9.(a)Notwithstanding Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code, the department shall have the authority to promulgate regulations as may be necessary to implement this article.
(b)The department may execute an interagency agreement with other state or local government agencies in the performance of any or all of the requirements of this section.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
As used in this article, the following terms have the following definitions:
(a)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. The total alkaloid content of kratom leaf material used in a kratom product shall not exceed 3.5 4 percent on a dried weight basis.
(b)Kratom leaf extract means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
(1)That contains an amount of residual solvent not to exceed the amount specified by the United States Food and Drug Administration guidance. in Chapter 467 of the United States Pharmacopeia and the National Formulary.
(2)That contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is equal to or more than twofold that of any other alkaloid present.
(3)The ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
(c)(1)Kratom product means a food food, ingredient, or dietary supplement that meets all of the following requirements:
(A)Consists of or contains kratom leaf or kratom leaf extract.
(B)Does not contain any synthesized kratom alkaloids or other synthesized kratom constituents, or synthesized metabolites of any kratom constituent.
(C)The level of 7-hydroxymitragynine on a percent weight basis is not greater than 1 percent of the amount of total kratom alkaloids confirmed with a high-pressure high-performance liquid chromatography or an ultra-performance liquid chromatography testing method.
(2)For purposes of this subdivision, synthesized means produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
(d)Processor means the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products.
(e)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.81.(a)A kratom product sold produced, manufactured, distributed, sold, or offered for sale, if consisting of or containing kratom leaf extract, shall not exceed the amount specified for pharmaceutical products in guidance offered by the United States Food and Drug Administration Chapter 467 of the United States Pharmacopeia and the National Formulary of any residual solvent used in manufacturing of the extract.
(b)A product containing a synthesized kratom alkaloid or other synthesized kratom constituents, or synthesized metabolites of a synthesized kratom constituent, shall not be produced, manufactured, distributed, sold, or offered for sale.
111224.82.A kratom product sold produced, manufactured, distributed, sold, or offered for sale shall have a label that clearly and conspicuously provides all of the following information on each retail package:
(a)A recommendation against the use by individuals who are under 21 years of age, who are pregnant, or who are breastfeeding.
(b)A recommendation to consult a health care professional prior to use.
(c)An advisement that kratom may be habit forming.
(d)The following statement: This product has These statements have not been evaluated by the United States Food and Drug Administration and Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
(e)The name and place of business of the processor, manufacturer, packer, or distributor.
(f)Directions for use that include all of the following:
(1)A recommended amount of the kratom product per serving.
(2)A recommended number of servings that can be safely consumed in a 24-hour period.
(3)Quantitative declarations of the amount per serving of each of the following:
(A)Total kratom alkaloids.
(B)Mitragynine.
(C)7-hydroxymitragynine.
111224.83.(a)A kratom product shall be packaged in a retail container that meets all of the following requirements:
(a)Clearly clearly marks the number of servings in the container.
(b)Contains no more than three servings. This subdivision applies only to products that meet all of the following conditions:(1)The kratom product is in liquid form.(2)The kratom product is sold in a container that is less than eight fluid ounces.(3)The kratom product does not include a calibrated measuring device.(c)If the kratom product is in liquid form, the container shall have clear serving size markings.(b)A kratom product offered for retail sale that is in liquid form and contains more than three servings shall include a calibrated measuring device.
(d)(c)If the kratom product is in powdered form, the package shall include a calibrated measuring device.
111224.84.(a)A processor shall register pursuant to Section 110460 111224.86 and shall annually register each kratom product it manufactures, packs, distributes, or labels. A product that contains the same kratom ingredients in the same kratom delivery form but a different container, package, or volume shall be included under the processors individual registration.
(b)Annual registration of a kratom product shall include a certificate of analysis from an independent laboratory. The laboratory shall be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
(c)The certificate of analysis shall confirm the contents of the kratom product, and include a certification that the product complies with the requirements for a kratom product described in Sections 111224.8 and 111224.81.
(d)Upon request by the department, a processor shall provide the actual results of a scientifically valid test that quantifies the amount of any or all kratom alkaloids, and any other constituent or substance that affects the quality or strength of a kratom product. The manufacturer shall certify that the kratom product does not contain a substance listed in Section 11054, 11055, 11056, 11057, or 11058.
(e)Upon a reasonable basis, receipt of evidence that suggests a kratom product may be adulterated, the department may require an independent third-party test of a registered kratom product by a laboratory of the departments choice, and the processor shall be required to submit payment for the test and equitable administrative fee within a reasonable timeframe. If the processor does not tender payment to the department within 30 days of receipt of the invoice for the testing and administrative fee, the department shall revoke the registration for that product.
111224.85.(a)An individual shall not sell individual, business, or other entity shall not sell, offer for sale, provide, or distribute kratom leaf or a kratom product to a person under 21 years of age.
(b)An online retailer or marketplace of kratom leaf or a kratom product shall implement an age-verification system to ensure compliance with subdivision (a).
111224.86.(a)The department, in implementing this article, may establish an annual fee or assessment for any processor registering to produce, manufacture, or offer for sale kratom leaf or a kratom product. Except as otherwise required by law, an individual or entity registering pursuant to this article is not required to register pursuant to Article 2 (commencing with Section 110460).
(b)Commencing February 1, 2026, and every February 1 thereafter, the department shall report to the Legislature and publish both of the following on its internet website:
(1)A list of estimated fees.
(2)A report of all costs for activities of the Kratom Consumer Protection Program, including, but not limited to, both of the following:
(A)Projected workload and costs for applicants and annual registrants, including workload costs for inspection and enforcement activities.
(B)A staffing and systems analysis to ensure efficient and effective utilization of fees collected, proper allocation of departmental resources to registration activities, inspections, complaint investigations, enforcement and appeal activities, and data collection and reporting.
(c) A report to be submitted pursuant to subdivision (b) shall be submitted in compliance with Section 9795 of the Government Code.
(d)The department may develop registration fees based on the number of units produced by registrants and total annual sales in California. The fee schedule may consist of tiers of registration fees denoted by unit production, total annual sales in California, and corresponding fees to the number of units produced and annual sales in California. The fees shall not exceed the reasonable regulatory costs of administering this article. The calculation of estimated fees is exempt from the Administrative Procedure Act (Chapter 3.5 (commencing with Section 11340) of Part 1 of Division 3 of Title 2 of the Government Code).
111224.87.A local authority shall not impose additional restrictions greater than those enumerated in this article or enact additional requirements on the manufacture of kratom leaf, kratom extract, or a kratom product.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
As used in this article, the following terms have the following definitions:
(a)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. The total alkaloid content of kratom leaf material used in a kratom product shall not exceed 3.5 percent on a dried weight basis.
(b)Kratom leaf extract means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
(1)That contains an amount of residual solvent not to exceed the amount specified by the United States Food and Drug Administration guidance.
(2)That contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is equal to or more than twofold that of any other alkaloid present.
(3)The ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
(c)(1)Kratom product means a food or dietary supplement that meets all of the following requirements:
(A)Consists of or contains kratom leaf or kratom leaf extract.
(B)Does not contain any synthesized kratom alkaloids or other kratom constituents, or synthesized metabolites of any kratom constituent.
(C)The level of 7-hydroxymitragynine on a percent weight basis is not greater than 1 percent of the amount of total kratom alkaloids confirmed with a high-pressure liquid chromatography testing method.
(2)For purposes of this subdivision, synthesized means produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
(d)Processor means the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products.
(e)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.81.A kratom product sold or offered for sale, if consisting of or containing kratom leaf extract, shall not exceed the amount specified for pharmaceutical products in guidance offered by the United States Food and Drug Administration of any residual solvent used in manufacturing of the extract.
111224.82.A kratom product sold or offered for sale shall have a label that clearly and conspicuously provides all of the following information on each retail package:
(a)A recommendation against the use by individuals who are under 18 21 years of age, who are pregnant, or who are breastfeeding.
(b)A recommendation to consult a health care professional prior to use.
(c)An advisement that kratom may be habit forming.
(d)The following statement: This product has not been evaluated by the United States Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.
(e)The name and place of business of the manufacturer, packer, or distributor.
(f)Directions for use that include all of the following:
(1)A recommended amount of the kratom product per serving.
(2)A recommended number of servings that can be safely consumed in a 24-hour period.
(3)Quantitative declarations of the amount per serving of each of the following:
(A)Total kratom alkaloids.
(B)Mitragynine.
(C)7-hydroxymitragynine.
111224.83.A kratom product shall be packaged in a retail container that meets all of the following requirements:
(a)Clearly marks the number of servings in the container.
(b)Contains no more than three servings. This subdivision applies only to products that meet all of the following conditions:
(1)The kratom product is in liquid form.
(2)The kratom product is sold in a container that is less than eight fluid ounces.
(3)The kratom product does not include a calibrated measuring device.
(c)If the kratom product is in liquid form, the container shall have clear serving size markings.
(d)If the kratom product is in powdered form, the package shall include a calibrated measuring device.
111224.84.(a)A processor shall register pursuant to Section 110460 and shall annually register each kratom product it manufactures, packs, distributes, or labels.
(b)Annual registration of a kratom product shall include a certificate of analysis from an independent laboratory. The laboratory shall be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
(c)The certificate of analysis shall confirm that the product complies with the requirements for a kratom product described in Sections 111224.8 and 111224.81.
(d)Upon request by the department, a processor shall provide the actual results of a scientifically valid test that quantifies the amount of any or all kratom alkaloids, and any other constituent or substance that affects the quality or strength of a kratom product.
(e)Upon a reasonable basis, the department may require an independent third-party test of a registered kratom product by a laboratory of the departments choice, and the processor shall be required to submit payment for the test and equitable administrative fee within a reasonable timeframe. If the processor does not tender payment to the department within 30 days of receipt of the invoice for the testing and administrative fee, the department shall revoke the registration for that product.
111224.85.An individual shall not sell kratom leaf or a kratom product to a person under 18 21 years of age.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
As used in this article, the following terms have the following definitions:
(a)Kratom leaf means the leaf of the kratom plant, also known as mitragyna speciosa, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. The total alkaloid content of kratom leaf material used in a kratom product shall not exceed 3.5 percent on a dried weight basis.
(b)Kratom leaf extract means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
(1)That contains an amount of residual solvent not to exceed the amount specified by the United States Food and Drug Administration guidance.
(2)That contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is equal to or more than twofold that of any other alkaloid present.
(3)The ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
(c)(1)Kratom product means a food or dietary supplement that meets all of the following requirements:
(A)Consists of or contains kratom leaf or kratom leaf extract.
(B)Does not contain any synthesized kratom alkaloids or other kratom constituents, or synthesized metabolites of any kratom constituent.
(C)The level of 7-hydroxymitragynine on a percent weight basis is not greater than 1 percent of the amount of total kratom alkaloids confirmed with a high-pressure liquid chromatography testing method.
(2)For purposes of this subdivision, synthesized means produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
(d)Processor means the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products.
(e)Total kratom alkaloids means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
111224.81.A kratom product sold or offered for sale, if consisting of or containing kratom leaf extract, shall not exceed the amount specified for pharmaceutical products in guidance offered by the United States Food and Drug Administration of any residual solvent used in manufacturing of the extract.
111224.82.A kratom product sold or offered for sale shall have a label that clearly and conspicuously provides all of the following information on each retail package:
(a)A recommendation against the use by individuals who are under 18 years of age, who are pregnant, or who are breastfeeding.
(b)A recommendation to consult a health care professional prior to use.
(c)An advisement that kratom may be habit forming.
(d)The following statement: This product has not been evaluated by the United States Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.
(e)The name and place of business of the manufacturer, packer, or distributor.
(f)Directions for use that include all of the following:
(1)A recommended amount of the kratom product per serving.
(2)A recommended number of servings that can be safely consumed in a 24-hour period.
(3)Quantitative declarations of the amount per serving of each of the following:
(A)Total kratom alkaloids.
(B)Mitragynine.
(C)7-hydroxymitragynine.
111224.83.A kratom product shall be packaged in a retail container that meets all of the following requirements:
(a)Clearly marks the number of servings in the container.
(b)Contains no more than three servings. This subdivision applies only to products that meet all of the following conditions:
(1)The kratom product is in liquid form.
(2)The kratom product is sold in a container that is less than eight fluid ounces.
(3)The kratom product does not include a calibrated measuring device.
(c)If the kratom product is in liquid form, the container shall have clear serving size markings.
(d)If the kratom product is in powdered form, the package shall include a calibrated measuring device.
111224.84.(a)A processor shall register pursuant to Section 110460 and shall annually register each kratom product it manufactures, packs, distributes, or labels.
(b)Annual registration of a kratom product shall include a certificate of analysis from an independent laboratory. The laboratory shall be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
(c)The certificate of analysis shall confirm that the product complies with the requirements for a kratom product described in Sections 111224.8 and 111224.81.
(d)Upon request by the department, a processor shall provide the actual results of a scientifically valid test that quantifies the amount of any or all kratom alkaloids, and any other constituent or substance that affects the quality or strength of a kratom product.
(e)Upon a reasonable basis, the department may require an independent third-party test of a registered kratom product by a laboratory of the departments choice, and the processor shall be required to submit payment for the test and equitable administrative fee within a reasonable timeframe. If the processor does not tender payment to the department within 30 days of receipt of the invoice for the testing and administrative fee, the department shall revoke the registration for that product.
111224.85.An individual shall not sell kratom leaf or a kratom product to a person under 18 years of age.
SEC. 2.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
SECTION 1.It is the intent of the Legislature to enact legislation to regulate kratom.It is the intent of the Legislature to enact legislation to regulate kratom.
|
Date
|
Status
|
|---|---|
| Aug 15, 2024 | In committee: Held under submission. |
| Jun 24, 2024 | In committee: Referred to suspense file. |
| Jun 17, 2024 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 13, 2024 | From committee: Amend, and do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (June 12). |
| May 29, 2024 | Referred to Com. on HEALTH. |
| May 22, 2024 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 21, 2024 | Read third time. Passed. Ordered to the Senate. (Ayes 73. Noes 0. Page 5371.) |
| May 20, 2024 | Read second time. Ordered to third reading. |
| May 16, 2024 | From committee: Amend, and do pass as amended. (Ayes 11. Noes 0.) (May 16). |
| May 16, 2024 | Read second time and amended. Ordered returned to second reading. |
| May 16, 2024 | Joint Rule 62(a), file notice suspended. (Page 5215.) |
| May 16, 2024 | Assembly Rule 63 suspended. |
| May 15, 2024 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 24, 2024 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 7. Noes 0.) (April 23). Re-referred to Com. on APPR. |
| Apr 22, 2024 | Re-referred to Com. on E.S. & T.M. |
| Apr 18, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on E.S. & T.M. Read second time and amended. |
| Apr 10, 2024 | From committee: Do pass and re-refer to Com. on E.S. & T.M. (Ayes 15. Noes 0.) (April 9). Re-referred to Com. on E.S. & T.M. |
| Mar 19, 2024 | Re-referred to Com. on HEALTH. |
| Mar 18, 2024 | Referred to Coms. on HEALTH and E.S. & T.M. |
| Mar 18, 2024 | From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended. |
| Feb 13, 2024 | From printer. May be heard in committee March 14. |
| Feb 12, 2024 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 24, 2024 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 12, 2024 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 21, 2024 | AB 2365 Haney Assembly Third Reading | Assembly Floor |
Passed |
|
| May 16, 2024 | Do pass as amended. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 23, 2024 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Environmental Safety and Toxic Materials |
Passed |
|
| Apr 9, 2024 | Do pass and be re-referred to the Committee on [Environmental Safety and Toxic Materials] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| American Kratom Association | * Against | Jun 24, 2024 |
| Arcadia Police Officers' Association | ** Support | |
| Burbank Police Officers' Association | ** Support | |
| California Association of Alcohol and Drug Program Executives | * Support | Jun 12, 2024 |
| California Coalition of School Safety Professionals | ** Support | |
| California District Attorneys Association | ** Support | |
| California Narcotic Officers Association | * Support | Jun 14, 2024 |
| California Reserve Peace Officers Association | ** Support | |
| CLAREMONT POLICE OFFICERS ASSOCIATION | ** Support | |
| Corona Police Officers Association | ** Support | |
| Culver City Police Officers' Association | ** Support | |
| Deputy Sheriffs Association of Monterey County | ** Support | |
| Fullerton Police Officers' Association | ** Support | |
| Global Kratom Coalition | * Support | Jun 14, 2024 |
| Los Angeles School Police Management Association | ** Support | |
| los angeles school police officers association | ** Support | |
| Murrieta Police Officers' Association | ** Support | |
| Newport Beach Police Association | ** Support | |
| Novato Police Officers Association | ** Support | |
| Palos Verdes Police Officers Association | ** Support | |
| Placer County Deputy Sheriffs' Assocation | ** Support | |
| Planted in Science Consulting, LLC | ** Support | |
| Pomona Police Officers' Association | ** Support | |
| RIVERSIDE POLICE OFFICERS ASSOCIATION | ** Support | |
| Riverside Sheriff's Association | * Support | Apr 23, 2024 |
| Santa Ana Police Officers Association | ** Support | |
| Upland Police Officers Association | ** Support |
SENATE COMMITTEE ON APPROPRIATIONS
Senator Anna Caballero, Chair
2023 - 2024 Regular Session
AB 2365 (Haney) - Public health: kratom
Version: June 17, 2024 | Policy Vote: HEALTH 10 - 0 |
Urgency: No | Mandate: Yes |
Hearing Date: June 24, 2024 | Consultant: Agnes Lee |
Bill Summary:
AB 2365 would establish the Kratom Consumer Protection Program to provide a regulatory structure for kratom products.
Fiscal Impact:
The California Department of Public Health (CDPH) estimates the following:
- Ongoing annual costs, ranging from $3,600,000- $4,076,000, with additional one-time costs in 2024-25 of $242,000 - $267,000, for staffing resources to license processors, conduct inspections, ensure compliance, conduct investigations, and compile and analyze data (including registration or failure to register kratom products per firm). CDPH cannot quantitatively determine the number of kratom processors or distributors that will be requesting licensure for selling kratom products in the state. To estimate the number of businesses that will be required to register their kratom products, CDPH assumes an approximate 5 percent increase in the number of new firms that would begin processing and distributing kratom products. CDPH assumes approximately 375-400 firms (high) and assumes only 25 percent would register voluntarily (low).
- Costs to begin the Project Approval Lifecycle (PAL) review and approval process for information technology (IT) requirements of $1.6 million over 17 months. The process would include an initial analysis to develop comprehensive planning that ensures the appropriate IT solution is selected and managed. The cost would be further refined and updated after all the required PAL planning stages are completed.
- Costs would be funded from the General Fund in the first two fiscal years, and from special fund revenues generated from the proposed manufacturer’s registration fees thereafter.
Background:
According to a November 2023 report by the Congressional Research Service, kratom is a tree related to the coffee plant and is native to parts of Southeast Asia. Peoples indigenous to the tree’s range have traditionally consumed the leaves of the tree for medicinal and other purposes. Users report both stimulant and sedative effects, believed to be caused by two compounds in the leaves: mitragynine, and 7-HO. Some commentators have raised safety concerns over kratom use, while others have suggested various beneficial uses.
According to the National Institute on Drug Abuse (NIDA), much is still unknown about chemical compounds related to kratom, the short- and long-term health and safety impacts of kratom use, and kratom’s potential therapeutic uses. NIDA supports and conducts research on kratom to help inform kratom policy and health decision-making around kratom use. People report using kratom products to alleviate drug withdrawal symptoms and cravings, particularly for opioids, to alleviate pain, and to help manage mental health problems.
The Food and Drug Administration (FDA) has not approved any drug products containing kratom, or its active compounds. However, the FDA has taken the position that kratom is an unapproved new dietary ingredient and therefore may not be marketed in the U.S. as either a nutritional supplement or a food additive. According to the FDA, it concluded from available information, including scientific data, that “kratom is a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such an ingredient does not present a significant or unreasonable risk of illness or injury,” and therefore is an adulterated product and cannot be lawfully marketed or added to food.
Proposed Law:
Specific provisions of the bill would:
- Require that a kratom product produced, manufactured, distributed, sold, or offered for sale, if consisting of or containing kratom leaf extract, cannot exceed the amount specified for pharmaceutical products in Chapter 467 of the United States Pharmacopeia and the National Formulary of any residual solvent used in manufacturing of the extract.
- Prohibit a product containing a synthesized kratom alkaloid or other synthesized kratom constituents, or synthesized metabolites of a synthesized kratom constituent, from being produced, manufactured, distributed, sold, or offered for sale.
- Require a kratom product produced, manufactured, distributed, sold, or offered for sale to have a label, as specified; and require a kratom product to be packaged in a retail container that clearly marks the number of servings in the container.
- Prohibit an individual, business, or other entity from selling, offering for sale, providing, or distributing kratom leaf or a kratom product to a person under 21 years of age.
- Prohibit an individual, business, or other entity from producing, selling, or distributing a kratom product that is attractive to children.
- Prohibit the manufacture or sale of an inhalable kratom product.
- Require a processor to register with the CDPH and annually register each kratom product it manufactures, packs, distributes, or labels; and authorize CDPH to establish an annual fee or assessment for any processor registering to produce, manufacture, or offer for sale kratom leaf or a kratom product.
- Require, commencing February 1, 2026, and every February 1 thereafter, the CDPH to report to the Legislature, as specified.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Richard Roth, Chair
BILL NO: AB 2365
AUTHOR: | Haney | ||
VERSION: | May 16, 2024 | ||
HEARING DATE: | June 12, 2024 | ||
CONSULTANT: | Vincent D. Marchand | ||
SUBJECT: Public health: kratom
SUMMARY:
Enacts the Kratom Consumer Protection Program to provide a regulatory structure for kratom products that requires manufacturers and distributors to register with the California Department of Public Health, adhere to certain requirements that include having products tested, and prohibit the sale to persons under 21.
Existing law:
- Enacts the Sherman Food, Drug and Cosmetic Law (Sherman Law), enforced by the California Department of Public Health (CDPH), which provides broad authority for CDPH to enforce food safety requirements, including that food is not adulterated, misbranded, or falsely advertised. Food labeling requirements generally adopt federal food labeling laws as the state requirement, including nutrition labeling and allergen labeling, but CDPH is permitted, by regulation, to adopt additional food labeling regulations. [HSC §109875, et seq.]
- Prohibits any person from engaging in the manufacturing, packing, or holding of any processed food unless the person has a valid registration as a food processing facility from the CDPH under the Sherman Law. [HSC §110460]
- Establishes penalties for violations of the Sherman Law, including a fine of up to $1,000, or up to $10,000 for repeated violations. [HSC §111825]
- Prohibits any manufacturer, wholesaler, retailer, or other person to sell, transfer, or otherwise furnish a dietary supplement containing either of the following to a person under 18 years of age:
- A dietary supplement containing an ephedrine group alkaloid; or
- A dietary supplement containing any of the following: androstanediol, androstanedione, androstenedione, norandrostenediol, norandrostenedione, dehydroepiandrosterone. [HSC §110423.2]
- Establishes a regulatory structure in CDPH, under the Sherman Law, for food, beverage and cosmetic products containing industrial hemp, and limits these products to containing no more than 0.3% concentration of tetrahydrocannabinol (THC). Prohibits industrial hemp from including cannabinoids produced through chemical synthesis. [HSC §111920 et seq., §111920(f)]
- Enacts the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to establish a comprehensive system to control and regulate the cultivation, distribution, transport, storage, manufacturing, processing, and sale of both medicinal cannabis and cannabis products, and adult-use cannabis and cannabis products for adults 21 years of age and over, regulated by the Department of Cannabis Control (DCC). [BPC §26000, et seq.]
This bill:
- Enacts the Kratom Consumer Protection Program, and defines the following terms for purposes of this bill:
- “Kratom leaf” means the leaf of the kratom plant, also known as mitragyna speciose, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedures, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. Prohibits the total alkaloid content of kratom leaf material used in a kratom product from exceeding 4% on a dried weight basis.
- “Kratom leaf extract” means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
- Contains an amount of residual solvent not to exceed an amount specified in the United States Pharmacopeia and the National Formulary;
- Contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is more than twofold that of any other alkaloid present; and,
- The ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
- “Kratom product” means a food, ingredient, or dietary supplement that meets all of the following requirements:
- Consists of or contains kratom leaf or kratom leaf extract;
- Does not contain any synthesized kratom alkaloids or other synthesized kratom constituents, or synthesized metabolites of any kratom constituent. Defines “synthesized,” for this purpose, as produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting; and,
- The level of 7-hydroxymitragynine (7-HO) on a percent weight basis is not greater than 1% of the amount of total kratom alkaloids confirmed with a high-performance liquid chromatography or an ultra-performance liquid chromatography testing method;
- “Processor” means the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products; and,
- “Total kratom alkaloids” means the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-HO in a kratom product.
- Prohibits a kratom product produced, manufactured, distributed, sold, or offered for sale, if consisting of or containing kratom leaf extract, from exceeding the amount specified for pharmaceutical products in the United State Pharmacopeia and the National Formulary for any residual solvent used in manufacturing of the extract.
- Prohibits a product containing a synthesized kratom alkaloid or other synthesized kratom constituents, or synthesized metabolites of a synthesized kratom constituent, from being produced, manufactured, distributed, sold, or offered for sale.
- Requires a kratom product produced, manufactured, distributed, sold, or offered for sale to have a label that clearly and conspicuously provides all of the following information on each retail package:
- A recommendation against the use by individuals who are under 21 years of age, who are pregnant, or who are breastfeeding;
- A recommendation to consult a health care professional prior to use;
- An advisement that kratom may be habit forming;
- The following statement: “These statements have not been evaluated by the United States Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease;”
- The name and place of business of the processor, manufacturer, packer, or distributor; and,
- Directions for use that include a recommended amount of the kratom product per serving, a recommended number of servings that can be safely consumed in a 24-hour period, and quantitative declarations of the amount per serving of each of the total kratom alkaloids, mitragynine, and 7-HO.
- Requires a kratom product to be packaged in a retail container that clearly marks the number of servings in the container.
- Requires a kratom product offered for retail sale that is in powdered form, or that is in liquid form and contains more than three servings, to include a calibrated measuring device.
- Requires a processor to register with CDPH in order to produce, manufacture, or offer for sale kratom leaf or a kratom product, and to annually register each kratom product it manufactures, packs, distributes, or labels. Specifies that if a product contains the same kratom ingredients in the same kratom delivery form but in a different container, package or volume, the product is required to be included under the processor’s individual registration.
- Requires the annual registration of a kratom product to include a certificate of analysis from an independent laboratory, which is required to be accredited under the standards of the International Organization for Standardization from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
- Requires the certificate of analysis from the independent laboratory to confirm the contents of the kratom product, and to include a certification that the product complies with the requirements of this bill.
- Requires the manufacturer to certify that the kratom product does not contain a controlled substance on any of the five schedules of controlled substances, as specified.
- Permits CDPH to require an independent third-party test of a registered kratom product by a laboratory of CDPH’s choice, upon receipt of evidence that suggests a kratom product may be adulterated, and requires the processor to submit payment for the test and equitable administrative fee within a reasonable timeframe. Requires CDPH to revoke the registration for the product if the processor does not tender payment to CDPH within 30 days of receipt of the invoice for the testing and administrative fee.
- Prohibits an individual, business, or other entity from selling, offering for sale, providing, or distributing kratom leaf or a kratom product to a person under 21 years of age. Requires an online retailer or marketplace of kratom leaf or a kratom product to implement an age-verification system to ensure compliance with this prohibition.
- Permits CDPH to establish an annual fee or assessment for any processor registering to produce, manufacture, or offer for sale kratom leaf or a kratom product. Requires CDPH, beginning on February 1, 2026, and every February 1 thereafter, to report to the Legislature and publish both of the following on its website: a list of estimated fees; and, a report of all costs for activities of the Kratom Consumer Protection Program, including projected workload and costs, and a staffing and systems analysis to ensure efficient and effective utilization of collected fees.
- Permits CDPH to develop registration fees based on the number of units produced by registrants and total annual sales in California. Exempts the calculation of estimated fees from the Administrative Procedures Act.
- Prohibits a local authority from imposing additional restrictions greater than those enumerated in this article, or from enacting additional requirements on the manufacture of kratom leaf, kratom extract, or a kratom product.
FISCAL EFFECT:
According to the Assembly Appropriations Committee, one-time General Fund costs of an unknown amount to CDPH, likely exceeding one million dollars, to establish processes, hire staff, promulgate regulations, and establish fees, among other activities. This bill authorizes CDPH to develop and collect registration fees that are not to exceed the reasonable costs to implement this bill; however, until CPDH is able to begin collecting fees, CDPH will require funds. According to the Legislative Analyst's Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years
PRIOR VOTES:
Assembly Floor: | 73 - 0 |
Assembly Appropriations Committee: | 11 - 0 |
Assembly ESTM Committee Assembly Health Committee: | 7 - 0 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, kratom is widely available throughout California. Some estimates show that nearly 25% of all kratom sales in the U.S. are in California alone. With the increase in demand for kratom, some manufacturers have irresponsibly created more potent and dangerous products. Without any kratom regulations, consumers can easily access products that can cause serious illness or harm. This bill will follow the lead of other states and ban high potency kratom, while making sure that safe kratom is accessible for consumers.
- Food and Drug Administration (FDA) regulation of dietary supplements. Under the federal Food, Drug, & Cosmetic Act (FD&C Act), as amended in 1994 by the Dietary Supplement Health and Education Act (often referred to as DSHEA), the FDA does not have the authority to approve dietary supplements for safety and effectiveness, or to approve their labeling, before the supplements are sold to the public. Instead, dietary supplements are regulated by the FDA in much the same manner as food, which means they are subject to requirements relating to good manufacturing practices, and must meet certain labeling standards, among other requirements. According to the FDA, it is the responsibility of dietary supplement companies to ensure their products meet the safety standards for dietary supplements and are not otherwise in violation of the law. Dietary supplement labels are required to have nutrition information in the form of a Supplement Facts label that includes the serving size, the number of servings per container, a listing of all dietary ingredients in the product, and the amount per serving of those ingredients. They also must have a statement on the front of the product identifying it as a “dietary supplement” or similar descriptive term (e.g., “herbal supplement” or “calcium supplement”). The FD&C Act requires that manufacturers and distributors who wish to market dietary supplements that contain a “new dietary ingredient” (NDI) to notify the FDA about these ingredients. An NDI is an ingredient that was not marketed in a dietary supplement in the U.S. prior to October 15, 1994. When notifying the FDA about an NDI, the notification must include information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing the NDI will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. While the FDA is not required to formally approve an NDI, it will consider a dietary supplement “adulterated” unless the NDI has been present in the food supply in the same chemical form that you plan to use in the dietary supplement, or the manufacturer has shown evidence of safety at least 75 days before being introduced or delivered for introduction into interstate commerce, including any citation to published articles.
- Background on kratom and its use. According to a November 2023 report by the Congressional Research Service, kratom is a tree related to the coffee plant and is native to parts of Southeast Asia. Peoples indigenous to the tree’s range have traditionally consumed the leaves of the tree for medicinal and other purposes. Users report both stimulant and sedative effects, believed to be caused by two compounds in the leaves: mitragynine, and 7-HO. Some commentators have raised safety concerns over kratom use, while others have suggested various beneficial uses. Additionally, some kratom products intended for sale in the U.S. have been found to contain dangerous contaminants, such as salmonella and heavy metals.
According to the National Institute on Drug Abuse (NIDA), much is still unknown about chemical compounds related to kratom, the short- and long-term health and safety impacts of kratom use, and kratom’s potential therapeutic uses. NIDA supports and conducts research on kratom to help inform kratom policy and health decision-making around kratom use. While kratom or its related compounds have not been approved by the FDA as safe and effective for any medical use, people report using kratom products to alleviate drug withdrawal symptoms and cravings, particularly for opioids, to alleviate pain, and to help manage mental health problems.
According to NIDA, people typically use kratom by swallowing raw plant matter in capsule or powder form, by mixing kratom powder into food or drinks, brewing the leaves as a tea, or taking liquid kratom extract. While estimates of the scope of kratom use vary, the expansion of kratom vendors and increasing case reports suggest that kratom use has become more common over the past two decades. According to the 2022 National Survey on Drug Use and Health by the Substance Abuse and Mental Health Services Administration, among people aged 12 or older, 0.7% (or 1.9 million people) used kratom. The percentage was highest among young adults aged 18 to 25 (1.1% or 371,000 people) followed by adults 26 or older, then by adolescents aged 12 to 17 (0.1% or 26,000 people). - How does it work, is it addictive, and the focus on 7-HO. According to NIDA, researchers are still learning how kratom and kratom compounds affect the body, as well as how short- and long-term kratom use may impact health. Like all drugs, kratom’s effects depend on the amount taken, potency, formulation of the product, the way it is ingested, other drugs in a person’s system, a person’s underlying medical conditions, and a person’s previous experience with the substance. While kratom leaves contain many chemical compounds (known as bioactive alkaloids), the most well studied are mitragynine and 7-HO. Mitragynine is found in kratom leaves and breaks down into 7-HO in the body when digested. Both activate opioid receptors, but the resulting effects only partially compare to those of opioids like heroin or oxycodone. Some research suggest that mitragynine and 7-HO may not cause some of the more serious adverse effects associated with opioid use, such as respiratory depression, that can occur during a life-threatening opioid overdose. Scientists have also observed that mitragynine may bind to adrenergic receptors, serotonin receptors, and dopamine receptors, which may be responsible for some of the arousing effects some people who use kratom report experiencing. In regard to whether it is addictive, NIDA states that studies suggest people may experience mild to moderate withdrawal symptoms when they stop regular kratom use, but more research is needed to understand to what extent people develop substance use disorder symptoms related to kratom. Preliminary data from anonymous surveys of people who use kratom suggest a minority of people report experiencing kratom withdrawal symptoms, and a smaller minority report experiencing substance use disorder symptoms. While some experts are concerned about kratom’s addictive potential because they activate the same sensors in the brain on which drugs with known addictive properties activate, researchers have observed that the way kratom compounds activate these receptors may reduce the potential for addiction.
This bill restricts the level of 7-HO in kratom products to no more than 1% of the total amount of kratom alkaloids. According to a 2019 article published in ACS Central Science, entitled “7-Hydroxymitragynine is an Active Metabolite of Mitragynine and a Key Mediator of its Analgesic Effects,” mitragynine is the major active alkaloid found in kratom, and that it is converted to the much more potent mu-opioid receptor agonist 7-HO in the liver. The study found that brain concentrations of 7-HO are sufficient to explain most or all of the opioid-receptor-mediated analgesic activity of mitragynine. At the same time, mitragynine was found in the brains of mice at very high concentrations relative to its opioid receptor binding affinity, suggesting that it does not directly activate opioid receptors. The results suggest a metabolism-dependent mechanism for the analgesic effects of mitragynine. - Can you overdose on kratom? According to NIDA, while more research is needed, it appears that fatal overdose from kratom use alone is extremely rare. A 2019 report found that 11 deaths between 2011 and 2017 in the U.S. were associated with kratom exposure, including two deaths associated with kratom exposure alone.
In response to questions from the author, CDPH has two sources of information related to whether kratom was found in relation to an overdose: death certificates, and an overdose monitoring system. CDPH notes that the overdose monitoring system uses voluntary reporting, and may not be generalizable to the state. According to CDPH, based on the available data, the following table shows the number of overdose deaths where kratom was found:
| 2019 | 2020 | 2021 | 2022 | 2023 |
Death Certificates with Kratom Present | 43 | 66 | 87 | 88 | 88 |
ONLY Kratom Toxicity | 2 | 7 | 13 | 7 | 12 |
Kratom with Another Substance Toxicity | 41 | 59 | 74 | 81 | 76 |
- Action on kratom at the federal level. According to the report by the Congressional Research Service, in 2016 the U.S. Drug Enforcement Agency (DEA) published notice of its intent to place mitragynine and 7-HO on Schedule I of the Controlled Substances Act, which would have criminalized possession of kratom and made distribution a felony. However, after receiving numerous comments from some members of Congress, advocacy groups, and others, the DEA withdrew that notice, and listed kratom as a Drug and Chemical of Concern, but has not exercised its authority to schedule kratom or its active compounds under the Controlled Substances Act.
Under the FD&C Act, the FDA regulates drugs and dietary supplements. The FDA has not approved any drug products containing kratom, or its active compounds. However, the FDA has taken the position that kratom is an unapproved new dietary ingredient and therefore may not be marketed in the U.S. as either a nutritional supplement or a food additive. According to the FDA, it concluded from available information, including scientific data, that “kratom is a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such an ingredient does not present a significant or unreasonable risk of illness or injury,” and therefore is an adulterated product and cannot be lawfully marketed or added to food. The FDA has issued a series of import alerts, most recently in July 2023, and authorized FDA personnel to seize imported kratom products from specified firms without physical inspection. FDA has also seized kratom products manufactured in the U.S., including an April 2023 seizure of kratom products worth approximately $3 million from an Oklahoma company.
In October of 2023, identical legislation was introduced in both the U.S. Senate and the House of Representatives to “protect access to kratom.” According to the Congressional Research Service, these bills would direct the Secretary of Health and Human Services to gather information about kratom and would limit the authority to impose regulations on kratom, including prohibiting requirements on kratom that are more restrictive than those for foods, dietary supplements, or dietary ingredients under the FD&C Act. Each bill would contain a non-preemption clause, which would permit states to either ban or regulate kratom. These bills have not progressed out of committee. - Action in other states. According to the Congressional Research Service, Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin currently ban mitragynine or 7-HO under state-law analogues of the Controlled Substances Act. However, legislators in four of these six states (Indiana, Rhode Island, Wisconsin, and Vermont) have introduced bills to replace existing bans with regulations that would permit the sale of kratom products. Tennessee regulates the sale of the kratom plant in its natural form but bans synthetic kratom alkaloids. As of the date of the Congressional Research Service’s report (November 2023), sixteen states regulate the sale of kratom products in some fashion, including eight states that have prohibited sales to persons under 18, and an additional eight states that prohibit sales to persons under 21 (this bill would also prohibit sales to those under 21). Regarding strength, Arizona, Oklahoma, Texas, and Utah prohibit sale of products in which 7-HO is greater than 2% of the total alkaloid content (this bill limits 7-HO to only 1% of the total alkaloid content).
- Related legislation. AB 82 (Weber) prohibits a retail establishment from selling dietary supplements for weight loss or over-the-counter (OTC) diet pills to any person under 18 years of age without a prescription. Requires CDPH to determine which dietary supplements and OTC diet pills are subject to this bill, and to develop a notice for distribution to retail establishments for posting that states that certain dietary supplements for weight loss or OTC diet pills may contribute to specified medical conditions or other serious injury, or death. AB 82 is pending in the Senate Judiciary Committee.
AB 2223 (Aguiar-Curry) permits cannabis licensees to manufacture, distribute, or sell products that contain industrial hemp, and establishes additional restrictions on industrial hemp products containing tetrahydrocannabinol (THC) or comparable cannabinoids. AB 2223 is set for hearing on June 24, 2024 in the Senate Business, Professions and Economic Development Committee. - Prior legislation. AB 45 (Aguiar-Curry, Chapter 576, Statutes of 2021) established a regulatory structure in CDPH for food, beverage and cosmetic products containing industrial hemp, and limited these products to containing no more than 0.3% concentration of THC.
SB 94 (Committee on Budget and Fiscal Review, Chapter 27, Statutes of 2017) establishes a single system of administration for cannabis laws in California, combining the Medicinal Cannabis Regulation and Safety Act with the Adult Use of Marijuana Act to create the Medicinal and Adult-Use Cannabis Regulation and Safety Act. - Support. This bill is supported by the Global Kratom Coalition, which includes a number of kratom manufacturers. The Coalition states that this bill is a crucial step toward protecting Californians by establishing essential market guidelines and regulations that promote transparency, quality, and safety within the kratom market. The Coalition points to the age limits, banning of harmful substances, labeling requirements, and testing and registration products as establishing a comprehensive framework for regulating kratom.
Attorney General Rob Bonta supports this bill, stating that kratom is widely available in California, and that some manufacturers have created stronger and more potent kratom concentrates to put into their products. Because there are no requirements on labeling or sale, anyone can purchase a dangerous product without their knowing, risking illness or severe harm. The Attorney General states that by banning the sale of dangerous products, this bill will make sure consumers can continue to use kratom safely. A large coalition of law enforcement organizations also support this bill, stating that this bill takes a first step in regulating this mind-altering substance and looks forward to working with the author in ensuring that kratom products available to the public are safe and not accessible to our youth. - Oppose unless amended. The Holistic Alternative Recovery Trust (HART) opposes this bill unless amended to reflect the evolving science behind the plant and its products. HART states that while it supports the overall thrust of the bill, it is deeply concerned that the proposed limit of 1% 7-HO in the product will sideline this emergent health and wellness alternative to opioids. HART states that it supports limiting 7-HO, but urges the Legislature to be cautious about imposing limits so low that the product loses its therapeutic and anti-opioid benefits, making kratom products useless to California consumers. HART states that research has already begun to show that the presence of 7-OH is crucial for pain relief effects, and that while the science is still evolving, early animal research shows promise. HART proposes modifying the limit from 1% to 2%. According to HART, this level, along with the other very important elements in the bill, will achieve the public safety objectives of the bill and allow kratom manufacturers to maintain financial viability while future research provides policymakers more knowledge about the benefits of kratom and 7-OH as well as any adverse effects.
- Policy comments. This bill is structured similarly to how industrial hemp products are regulated, which was enacted in 2021, and AB 2223 (Aguiar-Curry) which is currently pending in the Senate Business and Professions Committee, to add additional requirements at least partly based on lessons learned from the original legislation. Most of the following policy comments are based on language in either the original industrial hemp legislation, or are contained in AB 2223.
- Grandfathering clause? Given that there are products currently in the marketplace but there is not yet a registration process in place, any existing product would be unauthorized until the manufacturer was registered as a kratom producer. The author may wish to consider a provision to permit the manufacture and sale of kratom products, as long as the processors are operating in conformance with this bill, without being registered until CDPH establishes a registration process.
- Prohibition of inhalable products? When industrial hemp was authorized, the manufacture or sale of inhalable products was prohibited until the Legislature established a tax on inhalable hemp products, which has not happened yet. Similarly, the Committee may wish to ensure that inhalable kratom products are also prohibited.
- Embargo and seizure? One of the problems that grew out of the legalization of industrial hemp was a proliferation of illegal products without a strong regulatory structure to remove those products from the market. AB 2223 contains provisions to authorize peace officers and state officials to seize or embargo industrial hemp products that do not meet state requirements, and assigns fees and costs of seizing or embargoing products to the retailer unless the retailer proves that these costs should be assigned to the manufacturer. The author and Committee may wish to consider whether similar provisions should be added to this bill to ensure that illegal products can be swiftly removed from the marketplace.
- Provide CDPH with authority to adopt regulations to further regulate, including on serving size and packaging. The original industrial hemp bill gave CDPH the ability to determine maximum serving sizes, number of servings per container, and other requirements. AB 2223 additionally provides, if it is enacted, that any regulations filed within one year can be adopted as emergency regulations. Given that this bill, while it does require labels to specify serving sizes, does not establish a maximum dose of active alkaloids in a serving, the author and Committee may wish to expressly permit CDPH to adopt regulations on this and other matters.
- Prohibition on packaging and marketing to children. Since this bill prohibits the sale to those under 21 years of age, similar to cannabis products, the author and Committee may wish to consider whether a prohibition on marketing or packaging geared toward children should be added to this bill, which is prohibited in cannabis products.
SUPPORT AND OPPOSITION:
Support: Arcadia Police Officers’ Association
Attorney General Rob Bonta
Burbank Police Officers’ Association
California Association of Alcohol and Drug Program Executives
California Coalition of School Safety Professionals
California District Attorneys Association
California Narcotic Officers’ Association
California Reserve Peace Officers’ Association
Claremont Police Officers’ Association
Corona Police Officers Association
Culver City Police Officers’ Association
Deputy Sheriffs’ Association of Monterey County
Fullerton Police Officers’ Association
Global Kratom Coalition
Los Angeles School Police Management Association
Los Angeles School Police Officers’ Association
Murrieta Police Officers’ Association
Newport Beach Police Association
Novato Police Officers’ Association
Palos Verdes Police Officers’ Association
Placer County Deputy Sheriffs’ Association
Pomona Police Officers’ Association
Riverside Police Officers’ Association
Riverside Sheriffs’ Association
Santa Ana Police Officers’ Association
Shaterproof
Upland Police Officers’ Association
Six individuals
Oppose: Holistic Alternative Recovery Trust (unless amended)
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 2365
Author:(Haney)
As Amended Ver:May 16, 2024
Majority vote
SUMMARY
Requires the California Department of Public Health (DPH) to regulate the sale of kratom products and bans the sale of kratom products to individuals under 21 years of age.
Major Provisions
COMMENTS
Kratom. Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries. Kratom has a long history of use in Southeast Asia, where it is commonly known as thang, kakuam, thom, ketum, and biak. Traditionally, in Southeast Asia, people have chewed its leaves or made them into a tea that is used to fight fatigue and improve work productivity. The leaves may also be crushed and then smoked or placed into gel capsules. Kratom has also traditionally been used during religious ceremonies and to treat symptoms such as pain and diarrhea, sometimes as a substitute for opium. The alkaloid content refers to the various alkaloids that are present in the leaf material that contribute the effect of the plant, including mitragynine, paynantheine, speciogynine and speciociliatine.
Effects of Kratom Use. Kratom leaves contain two major psychoactive ingredients, mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain. People who use kratom have reported both stimulant-like effects (increased energy, alertness, rapid heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion). Per the U.S. Drug Enforcement Administration (DEA), consumption of kratom tree leaves produces a stimulant effect in low doses, and a sedative effect in high doses. Consumption of kratom in high doses can also lead to psychotic symptoms, and psychological and physiological dependence.
According to the National Center for Complementary and Integrative Health, some people use kratom to try to overcome opioid addiction, although kratom itself may have the potential to be addictive. People have reported using kratom to manage opioid withdrawal symptoms and cravings, and researchers are studying whether kratom is helpful for this purpose. However, kratom has not been shown to be safe and effective for this or any other medical use. Regular kratom users may experience withdrawal symptoms if they stop using it. A variety of side effects of kratom have been reported, including mild effects, such as nausea, constipation, dizziness, and drowsiness, and rare but serious effects such as seizures, high blood pressure, and liver problems. Fatal overdoses from kratom alone appear to be extremely rare; however, use of kratom in combination with other drugs has been linked to deaths and severe adverse effects such as liver problems.
According to the DEA, the abuse of kratom has increased markedly in recent years. Several cases of psychosis resulting from use of kratom have been reported, where individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion.
According to the Author
Kratom is widely available throughout California. Some estimates show that nearly 25% of all kratom sales in the U.S. are in California alone. With the increase in demand for kratom, some manufacturers have irresponsibly created more potent and dangerous products. Without any kratom regulations, consumers can easily access products that can cause serious illness or harm. The author concludes that this bill will follow the lead of other states and ban high potency kratom, while making sure that safe kratom is accessible for consumers.
Arguments in Support
According to the Global Kratom Coalition (GKC), a coalition of kratom distributors, manufacturers, processors, and industry leaders, this bill is a crucial step toward protecting Californians by establishing essential guidelines and regulations that promote transparency, quality, and safety within the kratom market. The GKC continues that this bill addresses the lack of regulation and universal standards in the kratom industry issue in the kratom industry, providing peace of mind to kratom users by assuring them that the products they buy meet stringent safety standards. The GKC believes that this bill's framework, among other things, will improve the market for our industry by setting widely accepted and well-tread manufacturing standards as the floor for kratom processing practices in California.
Arguments in Opposition
There is no known opposition.
FISCAL COMMENTS
According to the Assembly Appropriations Committee, one-time General Fund costs of an unknown amount to CDPH, likely exceeding one million dollars, to establish processes, hire staff, promulgate regulations, and establish fees, among other activities. This bill authorizes CDPH to develop and collect registration fees that are not to exceed the reasonable costs to implement this bill; however, until CPDH is able to begin collecting fees, CDPH will require funds. According to the Legislative Analyst's Office, the General Fund faces a structural deficit in the tens of billions of dollars over the next several fiscal years.
VOTES
ASM HEALTH: 15-0-1
YES: Bonta, Waldron, Aguiar-Curry, Arambula, Wendy Carrillo, Flora, Haney, Jones-Sawyer, Maienschein, McCarty, Joe Patterson, Rodriguez, Santiago, Schiavo, Weber
ABS, ABST OR NV: Sanchez
ASM ENVIRONMENTAL SAFETY AND TOXIC MATERIALS: 7-0-0
YES: Garcia, Hoover, Connolly, McKinnor, Papan, Reyes, Ta
ASM APPROPRIATIONS: 11-0-4
YES: Wicks, Arambula, Bryan, Calderon, Wendy Carrillo, Mike Fong, Grayson, Haney, Hart, Pellerin, Villapudua
ABS, ABST OR NV: Sanchez, Dixon, Jim Patterson, Ta
UPDATED
VERSION: May 16, 2024
CONSULTANT: Eliza Brooks / HEALTH / (916) 319-2097 FN: 0003308
Date of Hearing: May 15, 2024
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 2365
Author:(Haney) – As Amended Ver:April 18, 2024
Policy Committee: | Health | Vote: | 15 - 0 |
Environmental Safety and Toxic Materials | 7 - 0 | ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires the California Department of Public Health (CDPH) to regulate the sale of kratom products and bans the sale of kratom products to individuals under 21 years of age.
Specifically, this bill:
- Defines “kratom leaf,” “kratom leaf extract,” “kratom product,” and other terms.
- Requires a kratom processor, as defined, to annually register each of its kratom products with CDPH.
- Requires a kratom processor to include, when registering a product, a certificate of analysis from an accredited independent laboratory confirming the kratom product meets the specified requirements.
- Establishes labeling and packaging requirements for kratom products, including advice that the product may be habit-forming.
- Prohibits the sale of kratom products to individuals under 21 years of age.
FISCAL EFFECT:
One-time and ongoing General Fund costs of an unknown amount, likely exceeding one million dollars, to CDPH to develop a registration process for kratom producers, promulgate regulations, respond to questions from registrants, potential registrants, and external stakeholders, investigate complaints and refer substantiated complaints for enforcement action, and undertake other activities.
COMMENTS:
- Purpose. According to the author:
Kratom is widely available throughout California. Some estimates show that nearly 25% of all kratom sales in the US are in California alone. With the increase in demand for kratom, some manufacturers have irresponsibly created more potent and dangerous products. Without any kratom regulations, consumers can easily access products that can cause serious illness or harm. AB 2365 will follow the lead of other states and ban high potency kratom, while making sure that safe kratom is accessible for consumers.
- Background.
Kratom. Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries. Kratom has a long history of use in Southeast Asia, where it is commonly known as thang, kakuam, thom, ketum, and biak. Traditionally, in Southeast Asia, people have chewed its leaves or made them into a tea that is used to fight fatigue and improve work productivity. The leaves may also be crushed and then smoked or placed into gel capsules. Kratom has also traditionally been used during religious ceremonies and to treat symptoms such as pain and diarrhea, sometimes as a substitute for opium. The alkaloid content refers to the various alkaloids that are present in the leaf material that contribute the effect of the plant, including mitragynine, paynantheine, speciogynine and speciociliatine.
Effects of Kratom Use. Kratom leaves contain two major psychoactive ingredients, mitragynine and 7-hydroxymitragynine, which interact with opioid receptors in the brain. People who use kratom have reported both stimulant-like effects (increased energy, alertness, rapid heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion). Per the U.S. Drug Enforcement Administration (DEA), consumption of kratom tree leaves produces a stimulant effect in low doses, and a sedative effect in high doses. Consumption of kratom in high doses can also lead to psychotic symptoms, and psychological and physiological dependence.
According to the National Center for Complementary and Integrative Health, some people use kratom to try to overcome opioid addiction, although kratom itself may have the potential to be addictive. People have reported using kratom to manage opioid withdrawal symptoms and cravings, and researchers are studying whether kratom is helpful for this purpose. However, kratom has not been shown to be safe and effective for this or any other medical use. Regular kratom users may experience withdrawal symptoms if they stop using it. A variety of side effects of kratom have been reported, including mild effects, such as nausea, constipation, dizziness, and drowsiness, and rare but serious effects such as seizures, high blood pressure, and liver problems. Fatal overdoses from kratom alone appear to be extremely rare; however, use of kratom in combination with other drugs has been linked to deaths and severe adverse effects such as liver problems.
According to the DEA, the abuse of kratom has increased markedly in recent years. Several cases of psychosis resulting from use of kratom have been reported, where individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion.
- Support. This bill is supported by numerous law enforcement organizations.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 23, 2024
ASSEMBLY COMMITTEE ON ENVIRONMENTAL SAFETY AND TOXIC MATERIALS
Eduardo Garcia, Chair
ABPCA Bill Id:AB 2365 (
Author:Haney) – As Amended Ver:April 18, 2024
SUBJECT: Public health: kratom
SUMMARY: Adds kratom products to the Sherman, Food, Drug and Cosmetic Law; requires processors, as defined, to annually register their kratom products with the California Department of Public Health (CDPH); requires a certificate of analysis from an accredited independent laboratory as part of the registration confirming kratom products meets the specified requirements; establishes labeling and packaging requirements for kratom products; and, prohibits the sale of kratom products to individuals under 21 years of age. Specifically, this bill:
- Defines "kratom leaf" as the leaf of the kratom plant (mitragyna speciosa) in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients. The total alkaloid content of kratom leaf material used in a kratom product shall not exceed 3.5 percent on a dried weight basis.
- Defines "kratom leaf extract" as the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
- Contains an amount of residual solvent not to exceed the amount specified by the United States Food and Drug Administration (US FDA) guidance;
- Contains mitragynine as the most abundant alkaloid at a level that is equal to or more than twofold that of any other alkaloid present; and,
- Provides that the ratio of mitragynine to other alkaloids is the same or greater than that of the starting materials.
- Defines "kratom product" as a food or dietary supplement meeting the following requirements:
- Contains kratom leaf, or kratom leaf extract;
- Does not contain any synthesized kratom alkaloids or other kratom component or synthesized metabolites of any kratom component; and,
- Limits the level of 7-hydroxymitragynine on a percent weight basis to be less than 1 percent of the amount of total kratom alkaloids;
- For the purpose of kratom product, defines "synthesized" as produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
- Defines "processor" as the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself as manufacturing, preparing, packaging, or labeling kratom products.
- Defines "total kratom alkaloids" as the sum of mitragynine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
- States that amounts of residual solvents used in the manufacturing process in kratom products must comply with US FDA.
- Requires the following information on a label:
- Recommendation against the use by individuals under 21 years of age, individuals who are breastfeeding or pregnant;
- Recommendation to talk to a health care professional;
- Advisement that kratom may be habit forming;
- The statement: This product has not been evaluated by the United States Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease;
- Name and place of business of the manufacturer, packer, or distributor; and,
- Directions for use that include, recommended amount per serving, number of servings per 24-hour period, amounts of total kratom alkaloids, mitragynine and 7-hydroxymitragynine.
- Requires the following for a retail package container:
- Clearly marks the number of servings;
- Contains no more than three servings if the product is in liquid form, or the kratom product is sold in a container that is less than eight fluid ounces, or the kratom product does not include a calibrated measuring device.
- Has clear serving size markings if kratom product in liquid; and,
- Requires the package to come with a calibrated measuring device if kratom product is in powder form.
- Requires the processor to register each kratom product they manufacture, pack, distribute, or label.
- Requires the annual registration of kratom products to include a certificate of analysis from an independent laboratory. Requires the lab to be accredited under the standards of the International Organization of Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
- Requires the certificate of analysis to confirm that the product complies with the provisions of this bill.
- Requires a processor, upon request by CDPH, to provide the results of a valid test that quantifies the amount of any or all alkaloids and any other component or substance that affects the quality or strength of the kratom product.
- Authorizes CDPH, upon a reasonable basis, to require an independent third party test of a registered kratom product by a laboratory of their choice. The processor must submit payment for the test and equitable administrative fees in a reasonable timeframe.
- Requires CDPH to revoke the registration of a kratom product if the processor does not submit payment to the department within 30 days of receipt of the invoice for the testing and administrative fee.
- Prohibits an individual from selling kratom leaf or a kratom product to a person under 21 years of age.
EXISTING LAW:
- Prohibits, pursuant to the federal Food, Drug & Cosmetic Act (FD&C Act), the movement in interstate commerce of adulterated and misbranded food, drugs, devices, and cosmetics. (21 Code of Federal Regulations § 701.3)
- Establishes the Sherman Food, Drug, and Cosmetic Law (Sherman Law), administered by CDPH, which regulates the manufacture, packaging, labeling, and advertising of food, drugs, and cosmetics. (Health and Safety Code (HSC) § 111929.4)
Under the Sherman Food, Drug and Cosmetic Law:
- Defines "label" as a display of written, printed, or graphic matter upon a food, drug, device, or cosmetic or upon its immediate container. (HSC § 109955)
- Defines "manufacture" as the preparation, compounding, propagation, processing, or fabrication of any food, drug, device, or cosmetic. "Manufacture" includes repackaging or otherwise changing the container, wrapper, or labeling of any food, drug, device, or cosmetic in furtherance of the distribution of the food, drug, device, or cosmetic, but does not include repackaging from a bulk container by a retailer at the time of sale to its ultimate consumer. (HSC § 109970)
- Defines "package" as any container or wrapper that may be used by a manufacturer, producer, jobber, packer, or dealer for enclosing or containing any food, drug, device, or cosmetic. (HSC § 109990)
- Defines "person" as any individual, firm, partnership, trust, corporation, limited liability company, company, estate, public or private institution, association, organization, group, city, county, city and county, political subdivision of this state, other governmental agency within the state, and any representative, agent, or agency of any of the foregoing. (HSC § 109995)
- Requires all labels of foods, drugs, devices, or cosmetics to conform to federal requirements, as specified. (HSC § 110340)
- Requires the label of any package of a food, drug, device, or cosmetic that bears a representation as to the number of servings of the commodity contained in the package to bear a statement of the net quantity, in terms of weight, measure, or numerical count, of each serving. (HSC § 110345)
- Makes it unlawful for any person to advertise any food, drug, device, or cosmetic that is adulterated or misbranded. (HSC § 110398)
FISCAL EFFECT: Unknown
COMMENTS:
Need for the bill: According to the author:
"Kratom is widely available throughout California. Some estimates show that nearly 25% of all kratom sales in the US are in California alone. With the increase in demand for kratom, some manufacturers have irresponsibly created more potent and dangerous products. Without any kratom regulations, consumers can easily access products that can cause serious illness or harm. AB 2365 will follow the lead of other states and ban high potency kratom, while making sure that safe kratom is accessible for consumers."
Kratom: Kratom (Mitragyna speciosa) is a tropical tree native to Southeast Asia, the Philippines, and New Guinea. The leaves of this tree contain two major psychoactive ingredients (mitragynine and 7-hydroxymytragynine). Below are key definitions and drug information:
- Psychoactive: a drug or other substance that affects how the brain works and causes changes in mood, awareness, thoughts, feelings, or behavior. For example, alcohol, caffeine, certain pain medicines, heroin, cocaine, and amphetamines.
- Alkaloids: a class of nitrogen containing organic compounds found in bacteria, fungi, animals, and plants.
- Mitragynine: a major active alkaloid found in kratom making up two/thirds of the total alkaloid content in kratom. Mitragynine is considered a partial agonist of the opioid receptor.
- 7-hydroxymytragynine: an active metabolite of mitragynine (product of the breakdown of mitragynine). It is present in low quantities in kratom and it is a partial agonist of the opioid receptor.
Kratom Use: Kratom has been used for centuries during socioreligious ceremonies. In Thailand, it has been used to treat medical conditions like morphine dependence. In Malaysia, it is used as an opium substitute. Kratom leaves are crushed and then, smoked, brewed with tea or consumed in capsule form. Kratom leaves can also be chewed. Kratom is used to self-treat conditions such as pain, coughing, diarrhea, anxiety and depression, opioid use disorder, and opioid withdrawal.
Every year, within the United States Department of Health and Human Services, the Substance Abuse and Mental Health Services Administration (SAMHSA) sponsors and publishes the survey National Survey on Drug Use and Health. On November 2023, SAMHSA published Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. This report marked the third year in which respondents were asked about kratom use in the 12 months before the interview. Below is a table for the past three reports (most current first). The percentage was highest among young adults aged 18-25 every single year.
Age Group | Publication Year: 2023 Survey Year: 2022 | Publication Year: 2022 Survey Year: 2021 | Publication Year: 2021 Survey Year: 2020 |
12-17 years | 0.1% (26,000 people) | 0.2% (45,000 people) | 0.2% (48,000 people) |
18-25 years | 1.1% (371,000 people) | 0.8% (284,000 people) | 0.9% (286,000 people) |
26 or older | 0.7% (1.5 million people) | 0.6% (1.4 million people) | 0.8% (1.8 million people) |
% of respondents | 0.7% (1.9 million people) | 0.6 % (1.7 million people) | 0.8% (2.1 million people) |
The drug fact sheet for kratom, publicly available on the United States Drug Enforcement Administration (US DEA), states that at low doses, kratom can cause increased alertness, physical energy, and talkativeness. At high doses users experience sedative effects. The fact sheet also states that several cases of psychosis have been reported: individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion. Kratom’s effects on the body include nausea, itching, sweating, dry mouth, constipation, increased urination, tachycardia, vomiting, drowsiness, and loss of appetite. Users of kratom have also experienced anorexia, weight loss, insomnia, hepatotoxicity, seizure, and hallucinations.
According to Notes from the Field: Unintentional Drug Overdose Deaths with Kratom Detected — 27 States, July 2016–December 2017 (CDC report), published on April 2019 by the Centers for Disease Control and Prevention, 152 out of 27,338 (or 0.56%) of overdose deaths, tested positive for kratom on postmortem toxicology. Kratom was determined to be the cause of death for 91 of the 152 kratom positive deaths (59.9%), including seven that were only positive for kratom (additional substances cannot be ruled out). Almost all deaths had toxicology testing results that were positive for other substances including, but not limited to, fentanyl and heroine. Because kratom products are not properly regulated, information on the product safety, quality and use is not known in the context of these findings.
United States Food and Drug Administration (US FDA): The US FDA has not approved any prescription or over-the-counter drug products containing kratom or its two chemicals (mitragynine and 7-hydroxymitragynine). In other words, the US FDA has not evaluated the safety and effectiveness of kratom and its components in the treatment of any medical conditions. The US FDA has also concluded that there is not enough information to conclude that dietary supplements or food additive that contain kratom do not present a significant or unreasonable risk of illness or injury.
Consistent with statements on the US FDA website, on May 2023, Clinical Implications of Kratom (Mitragyna speciosa) Use: a Literature Review was published in the journal of Current Addiction Reports. The authors state that "Very few clinical reports of toxicity have been recorded among individuals using kratom alone and/or for the first time... more rigorous research on the clinical, pharmacodynamics [biochemical and physiological effects of drugs], and pharmacokinetic [movement and interaction of drugs in the body] aspects of kratom and MG [mitragynine] is needed to clarify the therapeutically useful or risky doses of kratom in humans." Executing rigorous research studies and collecting this data will likely take several years.
Proponents of the bill have highlighted a FDA dose-finding and safety pilot study that concludes servings sizes provided in the study were well tolerated by individuals. They also acknowledge that more research is needed for a comprehensive profile on safety and tolerability. On January 16, 2024, the FDA announced an open period of applications for a human abuse potential (HAP) study on the use of botanical kratom and " the pilot study is expected to provide critical information for conducting the HAP study, including information on the kratom dose, the botanical supply provider, and content for the Investigational New Drug application (e.g., safety information and chemistry manufacturing and controls data)."
National Institute on Drug Abuse (NIDA): NIDA currently supports and conducts research to evaluate the medicinal uses (effects, mechanisms and therapeutic potential) of kratom and related alkaloids. They state on their website that "compared to deaths from other drugs, a very small number of deaths have been linked to kratom products and nearly all cases involved other drugs or contaminants." There is concern about kratom's addictive potential due to mitragynine and 7-hydroxymitragynine's ability to activate subtypes of the opioid receptors. NIDA cites some research studies that includes in vivo studies (rodent studies) noting that the way kratom compounds bind to these receptors may reduce the potential for addiction relative to opioids. Robust clinical trials are needed to further advance understanding.
NIDA's website also points to primary literature that reports on people using kratom to ease cravings and withdrawal symptoms associated with other substances. On the subject of kratom withdrawal, they state that some studies suggest people may experience mild to moderate withdrawal symptoms when they stop kratom use, but more studies are warranted. On the subject of safety, they highlight that: kratom products may contain harmful contaminants; adverse effects range from mild to severe; a very small number of deaths have been linked to kratom products; drug interactions may influence effects; long-term health and safety effects are not well understood; effects on pregnancy are not well understood; and, safety effects of intoxication are not well understood.
Actions by the Federal Drug Enforcement Agency: In August 2016, the DEA announced that it would temporarily classify kratom's alkaloids, mitragynine and 7-hydroxymitragynine, as a Schedule I drug. According to the DEA's website, Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. The actions by the DEA were possible through the Controlled Substances Act, an act that gives the DEA authority to temporarily reclassify a substance to avoid an imminent hazard to public safety. After receiving backlash from advocates stating kratom was safer than prescription opioids, testimonials on its usefulness for managing pain and beneficial uses, and a bipartisan letter by U.S. Representatives calling for a delay on the ban, the DEA announced it would withdraw its intent to temporarily schedule kratom's alkaloids as a Schedule I drug. Thousands of comments were submitted in favor of kratom use and continued access. Currently, the DEA has listed kratom as a Drug and Chemical of Concern.
Actions within California: The city of San Diego banned the manufacturing, sale, distribution and possession of kratom since 2016. The city of Oceanside also prohibited the sale, distribution, possession and use of kratom in 2016. Newport Beach City Council approved an ordinance that would prohibit the sale and distribution of kratom. This ordinance took effect on April 2024.
Action by other states: Over the past decade there has been numerous actions put forth by different states. The Congressional Research Service Report titled, "Kratom Regulation: Federal Status and State Approaches," states that as of November 2023, Alabama (since May 2016), Arkansas (since October 2015), Indiana (since 2014), Rhode Island (since 2017), Vermont (since 2016) and Wisconsin (since 2014) currently ban mitragynine and 7-hydroxymitragynine. The states of Indiana, Rhode Island, Vermont, and Wisconsin have introduced legislation to replace the bans with regulations to allow for the sale of kratom products.
Actions by the Federal Government: On October 2023, The United States Senate and the United States House of Representatives introduced similar bills to protect access to kratom. The bills would require the Secretary of Health and Human Services to hold at least one hearing that allows for the discussion of the scientific data and information to date about the safety and use of kratom containing products or products derived from kratom marketed as a food, dietary ingredient, or dietary supplement. The scope of the hearing would include, among other things, input from scientific researchers, the degree of dependence or addiction associated with kratom, and potential benefits of kratom use. A task force to report on federally funded kratom-related research would also be formed allowing for ongoing evaluation of scientific findings.
Categories of regulation: For states that allow the sale of Kratom, the regulations cover different categories:
- Age restriction- Eight states ban the sale of kratom products for persons under 18 years of age. Eight other states ban the sale of kratom products to persons under 21 years of age. There is also legislation banning the possession by underage persons in some of these states.
- Marketing to children- Utah currently prohibits packaging or flavoring that appeals to children and requires safe packaging. West Virginia has recently passed legislation to address marketing to children.
- Adulteration and Contamination- Ten states have passed legislation that prohibit the sale of adulterated kratom products (contain non-kratom substances) or prohibit kratom products that are contaminated with harmful non-kratom substances.
- Strength- Four states have prohibited the sale of products if 7-hydroxymitragynine is greater than 2% of the alkaloid content.
- Labeling- Of the sixteen states that regulate Kratom sales, nine have regulations requiring labels to include one or a combination of the following: directions for safe use; warnings (e.g. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure or prevent any disease); information of the manufacturer or distributor; ingredients; alkaloid content; and/or factual basis that a product is a kratom product because it is derived from the kratom leaf.
- Testing and sampling- Four states have testing requirements to verify levels of alkaloid content, label information, heavy metal concentrations, contaminants (i.e. purity levels), and/or contamination with other drugs.
- Registration and permitting- Three states require registration with state agencies or obtaining state permits.
- Synthetic alkaloids-Four states define Kratom as not including synthetic kratom alkaloids. These states prohibit kratom products from being adulterated with synthetic compounds.
- Local authority- Colorado and Louisiana allow local authorities to adopt regulations on kratom or to ban kratom, but do not allow the sale of kratom to persons under 21 years of age.
- Private right of action- Oklahoma and Utah allow individuals to bring private civil actions for damages if they were harmed by violations of their kratom laws.
- Tax- West Virginia taxes kratom products.
The provisions of AB 2365 are very similar to existing regulations throughout the country and they cover several categories of regulation mentioned above. That is, they set an age restriction, require labeling to include directions of use, warnings, manufacture, packer or distributor information, alkaloid content, list of ingredients, and define kratom product to exclude synthetic alkaloids or synthetic components. The provisions of AB 2365 also requires testing of kratom products for compliance, registration of products, and gives authority to CDPH.
Regulation for safety: Previously cited data shows that more than 1.5 million Americans use kratom in some form. The events that unfolded when DEA announced intent to classify kratom's alkaloids as a Schedule I drug were actions by citizens that firmly believed in protecting the individual right to access a potentially therapeutic product, long used in other cultures. Proponents of the bill are in favor of regulating kratom to keep kratom users safe. Additionally, they state regulations are intended to also prevent "bad actors" in the industry and prevent a black market for kratom.
Heavy metals and other drugs: In 2018, the US FDA released a statement titled, "Statement by FDA Commissioner Scott Gottlieb, M.D., on risk of heavy metals, including nickel and lead, found in some kratom products" that reported the presence of heavy metals and warned consumers after testing some kratom products. About six months later, the US FDA released a second set of findings after testing more products and stated that "the analysis found significant levels of lead and nickel at concentrations that exceed safe exposure for oral daily drug intake." Without ensuring that kratom products are being tested for the presence of heavy metals, heavy kratom users may be exposed to heavy metal concentrations harmful to their health.
Postmortem toxicology data points from the CDC report cites fentanyl as the most frequently co-occurring substance. The data cannot confirm nor deny that kratom products were not adulterated with other dangerous drugs or that the kratom consumer was knowingly or unknowingly exposed to fentanyl. The state of Colorado has drafted legislation to prohibit kratom products that are adulterated with fentanyl or any other controlled substance.
Age: An age requirement in the bill of 21 years of age is consistent with current purchasing requirements for other habit forming products like tobacco and alcohol.
Testing requirements: The current language in the bill requires a certificate of analysis that confirms the product complies with (i) residual solvent amount guidelines established by the US FDA and (ii) the requirements listed to meet the definition of a kratom product.
The author may wish to consider including language that outlines testing requirements to test for the presence and amounts of heavy metals. For example, testing to verify the product does not contain harmful levels of lead or nickel. Consideration may also be given to other tests to ensure kratom products are not adulterated with illicit drugs.
Concentration of alkaloids: Average values of alkaloid concentrations in kratom are known. Ratios and concentration limits in AB 2365 are intended to limit "enhanced" products (addition of alkaloids to the product) in the market and align with native kratom leaf material and legislation in other states. A statement shared by a group of scientists explains the importance of these values:
"Mitragynine is metabolized in the human body to some degree into the active metabolite, 7- hydroxymitragynine. This 7-hydroxymitragynine metabolite has been shown to be associated with relatively greater abuse liability than its parent mitragynine, as it is more potent than mitragynine and 3- 22 times more potent than morphine at opioid receptors. The pharmacology of 7- hydroxymitragynine appears to differ from mitragynine in that is only acts on opioid receptors, rather than multiple systems in the human body…From a safety perspective, limiting the amount of both mitragynine, 7-hydroxymitragynine, and other alkaloids as has been done in most kratom-related state legislation, ensures that consumers are unlikely to experience adverse effects at commonly reported amounts of kratom ingestion."
As AB 2365 moves through the legislative process, the author's office may consider working with CDPH and health professionals to review the ratios and concentration limits.
This bill: AB 2365 would define kratom products and establish a set of requirements for kratom products under the Sherman, Food, Drug and Cosmetic Law. It would define processors and require them to register their kratom products with CDPH. As part of the registration process, a certificate of analysis from an accredited independent laboratory confirming kratom products meets the specified requirements would be required. Lastly, it would establish labeling and packaging requirements and would prohibit the sale of kratom products to individuals under 21 years of age.
Arguments in support: According to a coalition of law enforcement:
"While kratom use or sale has been banned or restricted in several countries, kratom products are currently legal and accessible online and in stores without restriction. AB 2365 takes a first step in regulating this mind-altering substance and we look forward to working with the author in ensuring that kratom products available to the public are safe and not accessible to our youth."
Additionally, the Global Kratom Coalition states:
"The CA KCPA [AB 2365, the California Kratom Consumer Protection Act] addresses the lack of regulation and universal standards in the kratom industry, providing peace of mind to kratom users by assuring them that the products they buy meet stringent safety standards. We believe that AB 2365’s framework, among other things, will improve the market for our industry by setting widely accepted and well tread manufacturing standards as the floor for kratom processing practices in California. AB 2365 does this in 5 ways:
- Manufacturing and Formulation Standards: AB 2365 would require vendors to adhere to specific safety guidelines and manufacturing practices. Consumers should expect with certainty that kratom products in California are uncontaminated, unadulterated, and contain a dosage level that is recognized as safe.
- Age Limits: The act would prohibit the sale of kratom to minors, emphasizing that individuals aged 18 and above are the intended consumers.
- Labeling and Disclosure: Under AB 2365, kratom processors must disclose allergens, ingredients, age requirements, physician and other safety warnings, directions for safe use, as well as the origin and content of mitragynine and 7-hydroxymitragynine in their products. Consumers will be able to make informed choices with these rules in place.
- Banning Harmful Substances: The measure would prohibit kratom products containing synthetic alkaloids that could compromise user safety.
- Testing and Registration Requirements: AB 2365 would require kratom processors to test and label their products accurately. Kratom processors would also be required to register with the Department of Public Health."
Arguments in opposition: None on file.
Related Legislation:
- AB 2217 (Weber). Prohibits, beginning January 1, 2027, a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains tianeptine. AB 2217 makes it a violation of these provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney. AB 2217 is pending a hearing in the Assembly Committee on Health.
- AB 82 (Weber). Prohibits a retail establishment from selling, transferring, or otherwise furnishing dietary supplements for weight loss or over-the-counter diet pills, as defined, to any person under 18 years of age without a prescription. AB 82 has been referred to the Senate Committee on Rules.
- AB 418 (Gabriel, Chapter 17, Statutes of 2023). Prohibits, beginning January 1, 2027, a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains any of the following: brominated vegetable oil, potassium bromate, propylparaben, and red dye 3.
- AB 1341 (Garcia 2022). Would have prohibited a retail establishment from selling, transferring, or otherwise furnishing dietary supplements for weight loss or over-the-counter diet pills, as defined, to any person under 18 years of age without a prescription, by requiring the retail establishment to follow a specified identification check. This bill was vetoed by Governor Gavin Newsom.
REGISTERED SUPPORT / OPPOSITION:
Support
Arcadia Police Officers' Association
Burbank Police Officers' Association
California Coalition of School Safety Professionals
California District Attorneys Association
California Narcotic Officers' Association
California Reserve Peace Officers Association
Claremont Police Officers Association
Corona Police Officers Association
Culver City Police Officers' Association
Deputy Sheriffs' Association of Monterey County
Fullerton Police Officers' Association
Global Kratom Coalition
Los Angeles School Police Management Association
Los Angeles School Police Officers Association
Murrieta Police Officers' Association
Newport Beach Police Association
Novato Police Officers Association
Palos Verdes Police Officers Association
Placer County Deputy Sheriffs' Assocation
Planted in Science Consulting, LLC
Pomona Police Officers' Association
Riverside Police Officers Association
Riverside Sheriffs' Association
Santa Ana Police Officers Association
Upland Police Officers Association
Opposition
None on file.
Analysis Prepared by: Brenda Cisneros-Larios / E.S. & T.M. /
Date of Hearing: April 9, 2024
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
ABPCA Bill Id:AB 2365 (
Author:(Haney) – As Amended Ver:March 18, 2024
SUBJECT: Public health: kratom.
SUMMARY: Adds kratom products to the Sherman Food, Drug, and Cosmetic Law (Sherman Law). Specifically, this bill:
- Prohibits a kratom product sold or offered for sale, if consisting of or containing kratom leaf extract, from exceeding the amount specified for pharmaceutical products in guidance offered by the federal Food and Drug Administration (FDA) of any residual solvent used in manufacturing of the extract.
- Requires a kratom product sold or offered for sale to have a label that clearly and conspicuously provides all of the following information on each retail package:
- A recommendation against the use by individuals who are under 18 years of age, who are pregnant, or who are breastfeeding;
- A recommendation to consult a health care professional prior to use;
- An advisement that kratom may be habit forming;
- The following statement: “This product has not been evaluated by the United States Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease;”
- The name and place of business of the manufacturer, packer, or distributor; and,
- Directions for use that include all of the following:
- A recommended amount of the kratom product per serving;
- A recommended number of servings that can be safely consumed in a 24-hour period; and,
- Quantitative declarations of the amount per serving of each of the following:
- Total kratom alkaloids;
- Mitragynine; and,
- 7-hydroxymitragynine.
- Requires a kratom product to be packaged in a retail container that meets all of the following requirements:
- Clearly marks the number of servings in the container;
- Contains no more than three servings. This subdivision applies only to products that meet all of the following conditions:
- The kratom product is in liquid form;
- The kratom product is sold in a container that is less than eight fluid ounces; and,
- The kratom product does not include a calibrated measuring device.
- Requires the container to have clear serving size markings if the kratom product is in liquid form; and,
- Requires the package to include a calibrated measuring device if the kratom product is in powdered form.
- Requires a processor to register pursuant to the Sherman Act and to annually register each kratom product it manufactures, packs, distributes, or labels.
- Requires annual registration of a kratom product to include a certificate of analysis from an independent laboratory. Requires the laboratory be accredited under the standards of the International Organization for Standardization 17025:2017 accreditation from an accreditation body that is a signatory to the International Laboratory Accreditation Cooperation Mutual Recognition Arrangement.
- Requires the certificate of analysis to confirm that the product complies with the requirements for a kratom product.
- Authorizes the Department of Public Health (DPH), upon a reasonable basis, to require an independent third-party test of a registered kratom product by a laboratory of the DPH’s choice, and requires the processor to submit payment for the test and equitable administrative fee within a reasonable timeframe.
- Requires DPH to revoke registration for a kratom product if the processor does not tender payment to the DPH within 30 days of receipt of the invoice for the testing and administrative fee.
- Prohibits an individual from selling kratom leaf or a kratom product to a person under 18 years of age.
- Defines a kratom leaf as the leaf of the kratom plant, also known as mitragyna speciosa, in fresh or dehydrated form, and subjected to no postharvest processing except for drying or size reduction, by cutting, milling, or similar procedure, and to cleaning or sterilization through application of heat, steam, pressurization, irradiation, or other standard treatments applied to food ingredients.
- Prohibits the total alkaloid content of kratom leaf material used in a kratom product from exceeding 3.5 % on a dried weight basis.
- Defines “kratom leaf extract” means the material obtained by extraction of kratom leaves with a solvent consisting of water, ethanol, or food grade carbon dioxide, or any other solvent authorized by regulation to be used in manufacturing a food ingredient and that meets all of the following requirements:
- Contains an amount of residual solvent not to exceed the amount specified by FDA guidance;
- Contains mitragynine as the most abundant alkaloid on a weight-by-weight basis and at a level that is equal to or more than twofold that of any other alkaloid present; and,
- Makes the ratio of mitragynine to other alkaloids is the same or greater than that of the starting material.
- Defines a “kratom product” as a food or dietary supplement that meets all of the following requirements:
- Consists of or contains kratom leaf or kratom leaf extract;
- Does not contain any synthesized kratom alkaloids or other kratom constituents, or synthesized metabolites of any kratom constituent; and,
- The level of 7-hydroxymitragynine on a percent weight basis is not greater than 1% of the amount of total kratom alkaloids confirmed with a high-pressure liquid chromatography testing method.
- Defines “synthesized” as produced using directed synthetic or biosynthetic chemistry rather than traditional food preparation techniques, such as heating or extracting.
- Defines “processor” as the party responsible for manufacturing, packaging, labeling, or distributing kratom products, or the party that advertises, represents, or holds itself out as manufacturing, preparing, packaging, or labeling kratom products.
- Defines “total kratom alkaloids” as the sum of mitragynine, speciociliatine, speciogynine, paynantheine, and 7-hydroxymitragynine in a kratom product.
EXISTING LAW:
- Provides, through the Sherman Law, for the regulation of various subjects relating to the processing, labeling, advertising, and sale of food, drugs, and cosmetics, including enriched food, under the administration and enforcement of DPH. [Health and Safety Code (HSC) § 109875-111929.4]
- Defines the following under the Sherman Law:
- A label to mean a display of written, printed, or graphic matter upon a food, drug, device, or cosmetic or upon its immediate container. [HSC §109955]
- Manufacture to mean the preparation, compounding, propagation, processing, or fabrication of any food, drug, device, or cosmetic. The term “manufacture” includes repackaging or otherwise changing the container, wrapper, or labeling of any food, drug, device, or cosmetic in furtherance of the distribution of the food, drug, device, or cosmetic. The term “manufacture” does not include repackaging from a bulk container by a retailer at the time of sale to its ultimate consumer. [HSC §109970]
- Requires all labels of foods, drugs, devices, or cosmetics to conform to with the requirements of the net quality of contents of the federal Fair Packaging and Labeling Act (Act) and the regulations pursuant to this Act. [HSC §110340]
- Provides that all food additive and food labeling regulations and any amendments to those regulations adopted pursuant to federal law are the regulations of this state, and authorizes DPH to prescribe conditions under which a food additive is allowed to be used in this state whether or not these conditions are in accordance with the regulations adopted pursuant to the federal law and to adopt additional food labeling regulations. [HSC § 110085]
- Prohibits the sale or distribution of any dietary supplement product that contains ephedrine group alkaloids unless the product contains a specified label. Permits the sale of any dietary supplement containing ephedrine if the product label clearly and conspicuously contains specified warnings, including the following:
- “WARNING: NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18 YEARS. DO NOT USE IF PREGNANT OR NURSING. Consult a physician or licensed qualified health care professional before using this product if you have, or have a family history of, heart disease, thyroid disease, diabetes, high blood pressure, depression or other psychiatric condition, glaucoma, difficulty in urinating, prostate enlargement, or seizure disorder, or if you are using a monoamine oxidase inhibitor or any other dietary supplement, prescription drug, or over-the-counter drug containing ephedrine, pseudoephedrine, or phenylpropanolamine (ingredients found in certain allergy, asthma, cough or cold, and weight control products).”
- “Do not exceed recommended serving. Exceeding recommended serving may cause serious adverse health effects, including heart attack and stroke.”
- “Discontinue use and call a physician or licensed qualified health care professional immediately if you experience rapid heartbeat, dizziness, severe headache, shortness of breath, or other similar symptoms.”
- “Individuals who are sensitive to the effects of caffeine should consult a licensed health care professional before consuming this product.”
- “KEEP OUT OF REACH OF CHILDREN.” [HSC § 110423(a)]
- “WARNING: NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18 YEARS. DO NOT USE IF PREGNANT OR NURSING. Consult a physician or licensed qualified health care professional before using this product if you have, or have a family history of, heart disease, thyroid disease, diabetes, high blood pressure, depression or other psychiatric condition, glaucoma, difficulty in urinating, prostate enlargement, or seizure disorder, or if you are using a monoamine oxidase inhibitor or any other dietary supplement, prescription drug, or over-the-counter drug containing ephedrine, pseudoephedrine, or phenylpropanolamine (ingredients found in certain allergy, asthma, cough or cold, and weight control products).”
- Prohibits the sale or distribution of dietary supplements containing steroid hormone precursors unless the product label for these dietary supplements clearly and conspicuously contains the following warning:
“WARNING: NOT FOR USE BY INDIVIDUALS UNDER THE AGE OF 18 YEARS. DO NOT USE IF PREGNANT OR NURSING. Consult a physician or licensed qualified health care professional before using this product if you have, or have a family history of, prostate cancer, prostate enlargement, heart disease, low “good” cholesterol, or if you are using any other dietary supplement, prescription drug, or OTC drug. Do not exceed recommended serving. Exceeding recommended serving may cause serious adverse health effects. Possible side effects include acne, hair loss, hair growth on the face (in women), aggressiveness, irritability, and increased levels of estrogen. Discontinue use and call a physician or licensed qualified health care professional immediately if you experience rapid heartbeat, dizziness, blurred vision, or other similar symptoms. KEEP OUT OF REACH OF CHILDREN.” [HSC § 110423(b)] - Requires the product label for any dietary supplement product containing ephedrine group alkaloids or steroid hormone precursors to clearly and conspicuously display the following statement: “To report any adverse events call 1-800-332-1088” [MedWatch program]. [HSC § 110423(c)]
- Establishes the California Unfair Practices which prohibits unfair competition and any unlawful, unfair or fraudulent business act or practice and unfair, deceptive, untrue or misleading advertising. [Business and Professions Code (BPC) § 17500]
- Requires the product label for any dietary supplement product containing ephedrine group alkaloids or steroid hormone precursors to clearly and conspicuously display the following statement: “To report any adverse events call 1-800-332-1088” [MedWatch program]. [HSC § 110423(c)]
- Makes it a misdemeanor to sell, furnish, give, or cause to be sold, furnished, or given away, any alcoholic beverage to any person under the age of 21 years. Makes it a misdemeanor for any person under the age of 21 years to purchase any alcoholic beverage, or to consume any alcoholic beverage, as specified. [BPC § 25658]
- Requires all persons engaging in the retail sale of tobacco products to check the ID of tobacco purchasers, to establish the age of the purchaser, if the purchaser reasonably appears to be under 21. [BPC § 22956]
FISCAL EFFECT: Unknown. This bill has not yet been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, kratom is widely available throughout California. Some estimates show that nearly 25% of all kratom sales in the US are in California alone. With the increase in demand for kratom, some manufacturers have irresponsibly created more potent and dangerous products. Without any kratom regulations, consumers can easily access products that can cause serious illness or harm. The author concludes that this bill will follow the lead of other states and ban high potency kratom, while making sure that safe kratom is accessible for consumers.
- BACKGROUND.
- What is kratom? Kratom (Mitragyna speciosa) is a tree in the coffee family, found in Thailand and neighboring countries. These leaves are crushed and then smoked, brewed with tea, or placed into gel capsules. Kratom has a long history of use in Southeast Asia, where it is commonly known as thang, kakuam, thom, ketum, and biak. Traditionally, in Southeast Asia, people have chewed its leaves or made them into a tea that is used to fight fatigue and improve work productivity. Kratom has also traditionally been used during religious ceremonies and to treat symptoms such as pain and diarrhea, sometimes as a substitute for opium. In this bill, kratom leaf refers to the leaf of a kratom plant, in either fresh or dehydrated form, that has not been processed except for drying or size reduction and cleaning or sterilization. The alkaloid content refers to the various alkaloids that are present in the leaf material that contribute the effect of the plant, including mitragynine, paynantheine, speciogynine and speciociliatine.
- Effects of kratom usage. Kratom leaves contain two major psychoactive ingredients, mitragynine and 7-hydroxymitragynine, interact with opioid receptors in the brain. People who use kratom have reported both stimulant-like effects (increased energy, alertness, rapid heart rate) and effects like those of opioids and sedatives (relaxation, pain relief, confusion). Per the US Drug Enforcement Administration (DEA), consumption of kratom tree leaves produces a stimulant effect in low doses, and a sedative effect in high doses. Consumption of kratom in high doses can also lead to psychotic symptoms, and psychological and physiological dependence.
According to the National Center for Complementary and Integrative Health, people may use kratom to try to overcome opioid addiction, kratom itself may have the potential to be addictive. People have reported using kratom to manage opioid withdrawal symptoms and cravings, and researchers are studying whether kratom is helpful for this purpose. However, kratom has not been shown to be safe and effective for this or any other medical use. Regular kratom users may experience withdrawal symptoms if they stop using it. A variety of side effects of kratom have been reported. They include mild effects, such as nausea, constipation, dizziness, and drowsiness, and rare but serious effects such as seizures, high blood pressure, and liver problems. Fatal overdoses from kratom alone appear to be extremely rare. The use of kratom in combination with other drugs has been linked to deaths and severe adverse effects such as liver problems. More research is needed on drug interactions involving kratom. The long-term effects of kratom use are not well understood. There have been reports that long-term use of large doses of kratom may cause serious liver problems in some people. Harmful contaminants such as heavy metals and disease-causing bacteria have been found in some kratom products.
According to the DEA, the abuse of kratom has increased markedly in recent years. Several cases of psychosis resulting from use of kratom have been reported, where individuals addicted to kratom exhibited psychotic symptoms, including hallucinations, delusion, and confusion.
- Research on kratom use. According to a study published in the National Library of Medicine in 2019 on perspectives of the impact of kratom use, the national poison center reporting database documented 1,807 calls related to kratom exposure from 2011 to 2017. The Centers for Disease Control and Prevention analyzed data on unintentional and undetermined opioid overdose deaths from the State Unintentional Drug Overdose Reporting System. Kratom was detected on postmortem toxicology testing in 152 cases of 27,338 overdose deaths from data collected from 11 states during July 2016-June 2017 and 27 states during July–December 2017. Kratom was identified as the cause of death by a medical examiner in 91 of the 152 kratom-positive deaths, but was the only identified substance in just seven of these cases. Presence of additional substances in these seven kratom-only cases cannot be ruled out. The co-occurring substances in the 91 cases where kratom was identified as the cause of death include fentanyl (including analogs), heroin, benzodiazepines, prescription opioids, cocaine, and alcohol. Multi-substance exposures involving kratom, predominantly in combination with opioids, are associated with a greater odds ratio of admittance to a health care facility and occurrence of a serious medical outcome when compared to kratom-only exposure. These data highlight that kratom use is associated with a complex population of poly-drug users and especially with opioid use disorder. These data further suggest that a deeper investigation into the toxicity of kratom is needed, especially focusing on drug–herb interactions.
- Legal Status of Kratom.
- National level. Kratom is currently legal and accessible online and in stores in many areas of the United States. In 2016, DEA published notice of its intent to place mitragynine and 7-hydroxymitragynine in Schedule I on an emergency basis, which would have criminalized possession of kratom and made distribution a felony. However, after receiving numerous comments from some Members of Congress, advocacy groups, and others, DEA withdrew that notice. DEA has listed kratom as a Drug and Chemical of Concern but to date has not exercised its authority to schedule kratom or its active compounds under the federal Controlled Substances Act. Even though the DEA has listed kratom as a “drug of concern,” but kratom and kratom compounds are not listed in the U.S. schedule of controlled substances. The FDA has not approved kratom as safe and effective for any medical purpose. Under the Federal Food, Drug, and Cosmetic Act, kratom is considered a new dietary ingredient since it was not marketed as a dietary ingredient in the United States before October 15, 1994; evidence of safety is required for new dietary ingredients. FDA has issued a series of import alerts, most recently in July 2023, authorizing FDA personnel to seize imported kratom products from specified firms without physical inspection. FDA has also seized kratom products manufactured in the United States, including an April 2023 seizure of kratom products worth approximately $3 million from an Oklahoma company. In October 2023, Members introduced essentially identical bills in both the House and the Senate to “protect access to kratom.” Members introduced similar bills in the House and the Senate in the 117th Congress. These bills would neither ban kratom nor impose new regulations on kratom. Instead, the bills would direct the Secretary of Health and Human Services (the Secretary) to gather information about kratom and would limit the Secretary’s authority to impose regulations on kratom. The bills would require the Secretary to hold at least one public hearing to discuss the safety of kratom products. That hearing would have to cover several specified topics, including any potential benefits of kratom usage and any adverse health impacts of a kratom ban. The bills would also require the Secretary to establish a task force to coordinate and report on federally funded kratom-related research. Before promulgating any new rule regulating kratom, the Secretary would have to follow procedures for formal rulemaking and to have public, in-person hearings. The bills would prohibit the Secretary from: imposing requirements on kratom that are more restrictive than those for foods, dietary supplements, or dietary ingredients under the Federal Food, Drug, and Cosmetic Act; requiring kratom to follow the notification requirements for new dietary ingredients; using certain specified grounds to treat kratom as an adulterated dietary supplement; or enforcing any import alert for kratom products absent evidence that the particular product is adulterated. Each bill contains a nonpreemption provision, which would leave existing state laws—whether banning kratom or regulating it—in place.
- Other States.
- Kratom bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin currently ban mitragynine and hydroxymitragynine or 7-hydroxymitragynine (kratom’s active alkaloids). Legislators in Indiana, Rhode Island, Wisconsin, and Vermont have introduced bills to replace existing bans with regulations that would permit the sale of kratom products.
- Age restriction: Age restriction: Arizona, Georgia, Illinois, Minnesota, Nevada, Oklahoma, Texas, and Utah ban sales to persons under 18 years of age.
- Strength: Arizona, Oklahoma, Texas, and Utah prohibit sale of products in which 7-hydroxymitragynine is greater than 2% of the total alkaloid content.
- Labeling: Nine of the 16 states with laws regulating kratom sales require labels on kratom products, but the content required varies by state. Texas, Nevada, Georgia, and Oklahoma require that kratom products include labels with directions for safe or suggested use. Utah and Virginia require that labels bear a warning that the product may be harmful; has not been evaluated by the FDA; and is not intended to diagnose, treat, cure, or prevent any disease. West Virginia requires the commissioner of agriculture to develop labeling standards, which must include warnings to keep the product out of reach of children and to consult a physician before use if pregnant or taking medication. Colorado (effective July 1, 2024), Georgia, and Oklahoma require that labels state the identity and address of the product’s manufacturer or distributor. Arizona, Georgia, Oklahoma, and Utah require that labels state the amount of mitragynine and 7- hydroxymitragynine in the product. Colorado (effective July 1, 2024), Nevada, and Virginia require labels listing all ingredients. Georgia and Oklahoma require a list of ingredients that includes common names. Oklahoma law requires kratom vendors to provide, upon request of the Oklahoma Department of Health, test results from a “United States-based testing facility” confirming the items on the label. Oregon requires third-party testing for microbiological contaminants, pesticides, solvents, heavy metals, and mycotoxins. Utah requires a certificate of analysis from a certified third-party laboratory indicating the results of testing for alkaloid content and levels of pathogens and specified heavy metals. The state periodically tests kratom products to confirm those certificates of analysis and may test for pesticides, fentanyl derivatives, cannabinoids, cocaine, and benzodiazepines. Oregon and Utah require kratom sellers to register with state agencies. West Virginia requires kratom sellers to obtain state permits.
- Local authority: Colorado and Louisiana explicitly allow localities to adopt stricter controls on kratom or to ban kratom completely but do not allow localities to permit sales to persons under 21 years of age.
- Kratom bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin currently ban mitragynine and hydroxymitragynine or 7-hydroxymitragynine (kratom’s active alkaloids). Legislators in Indiana, Rhode Island, Wisconsin, and Vermont have introduced bills to replace existing bans with regulations that would permit the sale of kratom products.
- Kratom in California. Some estimates show that nearly 25% of all kratom sales in the United States are in California. In March 2024, the city of Newport Beach approved an ordinance to prohibit the sale and distribution of kratom. The City of San Diego and Oceanside banned the use and sale of kratom in 2016. It has been reported that some manufacturers have created stronger and more potent kratom concentrates to put into their products. This bill seeks to regulate kratom. This bill states that the total alkaloid content of kratom leaf material used in a kratom leaf product shall not exceed 3.5 % on a dried weight basis. The Global Kratom Coalition, who supports this bill, states that this number is based on studies in which the alkaloid content of kratom leaf material in a kratom product did not go above 2.5%. The Global Kratom Coalition contends that putting in a limit of the total alkaloid content of kratom leaf material used in a kratom product based on what has been seen natural will ensure that the leaf material is not altered post harvest to make it more potent, as alteration may make the product unsafe. This bill states that the level of 7-hydroxymitragynine on a percent weight basis is not greater than 1% of the amount of total kratom alkaloids confirmed with a high pressure. According to research provided by the sponsors published by the National Library of Medicine, older reports have shown the level of 7-hydroxymitragynine in the total alkaloid content in a kratom product can reach up to 2%, but water or ethanolic extracts and dried leaf material contain 7-hydroxymitragynine at no more than 1% of the total alkaloid content in the product. The coalition contends that limiting the amount of 7-hydroxymitragynine to 1% will ensure that kratom users are unlikely to experience adverse events at commonly reported serving levels.
- Research on kratom use. According to a study published in the National Library of Medicine in 2019 on perspectives of the impact of kratom use, the national poison center reporting database documented 1,807 calls related to kratom exposure from 2011 to 2017. The Centers for Disease Control and Prevention analyzed data on unintentional and undetermined opioid overdose deaths from the State Unintentional Drug Overdose Reporting System. Kratom was detected on postmortem toxicology testing in 152 cases of 27,338 overdose deaths from data collected from 11 states during July 2016-June 2017 and 27 states during July–December 2017. Kratom was identified as the cause of death by a medical examiner in 91 of the 152 kratom-positive deaths, but was the only identified substance in just seven of these cases. Presence of additional substances in these seven kratom-only cases cannot be ruled out. The co-occurring substances in the 91 cases where kratom was identified as the cause of death include fentanyl (including analogs), heroin, benzodiazepines, prescription opioids, cocaine, and alcohol. Multi-substance exposures involving kratom, predominantly in combination with opioids, are associated with a greater odds ratio of admittance to a health care facility and occurrence of a serious medical outcome when compared to kratom-only exposure. These data highlight that kratom use is associated with a complex population of poly-drug users and especially with opioid use disorder. These data further suggest that a deeper investigation into the toxicity of kratom is needed, especially focusing on drug–herb interactions.
- SUPPORT. According to the Global Kratom Coalition (GKC), a coalition of kratom distributors, manufacturers, processors, and industry leaders, this bill is a crucial step toward protecting Californians by establishing essential guidelines and regulations that promote transparency, quality, and safety within the kratom market. The GKC continues that this bill addresses the lack of regulation and universal standards in the kratom industry issue in the kratom industry, providing peace of mind to kratom users by assuring them that the products they buy meet stringent safety standards. The GKC believes that this bill’s framework, among other things, will improve the market for our industry by setting widely accepted and well-tread manufacturing standards as the floor for kratom processing practices in California.
- RELATED LEGISLATION.
- AB 2217 (Weber) prohibits, commencing January 1, 2027, a person or entity from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains tianeptine. AB 2217 makes it a violation of these provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney. AB 2217 is pending a hearing in the Assembly Committee on Health. Should this bill pass out of this committee, it will be referred to the Assembly Committee on Judiciary.
- AB 1830 (Arambula) requires a manufacturer of corn masa flour (CMF) to add folic acid at a level not to exceed 0.7 milligrams of folic acid per pound of CMF and to include a declaration of folic acid on the nutrition label in accordance with applicable federal law. AB 1830 is pending a hearing in the Assembly Committee on Appropriations.
- AB 2223 (Aguiar-Curry) of 2024 would state that the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) does not prohibit a licensee from manufacturing, processing, distributing, or selling products that contain industrial hemp or cannabinoids, extracts, or derivatives from industrial hemp if the product complies with all applicable state laws and regulations. AB 2223 is pending a hearing in Assembly Business and Professions Committee.
- AB 82 (Weber) of 2023 prohibits a retail establishment from selling, transferring, or otherwise furnishing dietary supplements for weight loss or over-the-counter diet pills, as defined, to any person under 18 years of age without a prescription. AB 82 has been referred to the Senate Committee on Rules.
- PREVIOUS LEGISLATION.
- AB 418 (Gabriel), Chapter 328, Statutes of 2023, prohibits a person or entity, commencing January 1, 2027, from manufacturing, selling, delivering, distributing, holding, or offering for sale, in commerce a food product for human consumption that contains any of the following substances: Brominated vegetable oil; Potassium bromate; Propylparaben; or Red dye 3. AB 418 makes a violation of its provisions punishable by a civil penalty not to exceed $5,000 for a first violation and not to exceed $10,000 for each subsequent violation, upon an action brought by the Attorney General, a city attorney, a county counsel, or a district attorney.
- AB 420 (Aguiar-Curry) of 2023 would have specified that MAUCRSA does not prohibit a cannabis licensee from manufacturing, distributing, or selling industrial hemp products if the product complies with applicable laws and regulations governing industrial hemp. AB 420 was held on the Senate Appropriations suspense file.
- DOUBLE REFERRAL. This bill is double-referred, upon passage of this committee, it will be referred to the Assembly Committee on Environmental Safety and Toxic Materials.
- POLICY COMMENT. As this bill moves through the process, the author may wish to consider working with DPH and other stakeholders to determine the appropriate total alkaloid content of kratom leaf material used in a kratom product, and the appropriate level of mitragynine and 7-hydroxymitragynine on a percent weight basis within a kratom product.
REGISTERED SUPPORT / OPPOSITION:
Support
Arcadia Police Officers' Association
Burbank Police Officers' Association
California Coalition of School Safety Professionals
California District Attorneys Association
California Narcotic Officers' Association
California Reserve Peace Officers Association
Claremont Police Officers Association
Corona Police Officers Association
Culver City Police Officers' Association
Deputy Sheriffs' Association of Monterey County
Fullerton Police Officers' Association
Global Kratom Coalition
Los Angeles School Police Management Association
Los Angeles School Police Officers Association
Murrieta Police Officers' Association
Newport Beach Police Association
Novato Police Officers Association
Palos Verdes Police Officers Association
Placer County Deputy Sheriffs' Association
Planted in Science Consulting, LLC
Pomona Police Officers' Association
Riverside Police Officers Association
Riverside Sheriffs' Association
Santa Ana Police Officers Association
Upland Police Officers Association
Opposition
None on file.
Analysis Prepared by: Eliza Brooks / HEALTH / (916) 319-2097
Discussed in Hearing
Senate Standing Committee on Appropriations
Senate Standing Committee on Health
Assembly Floor
Assembly Standing Committee on Environmental Safety and Toxic Materials
Assembly Standing Committee on Health
Bill Author
Bill Co-Author(s):